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Simple Summary: The intestinal epithelium—a single-cell layer lining the luminal surface of the
small and large intestine—comprises an array of highly specialized cell types that perform diverse
digestive functions while also forming a protective barrier against potentially toxic gut contents. As
such, the intestinal epithelium is barraged by multiple extraneous stresses and undergoes constant
renewal to replenish lost or damaged cells. This perpetual renewal is orchestrated by LGR5+ stem
cells in response to multiple convergent instructive signals, emanating from cells in the immediate
vicinity, collectively termed the intestinal stem cell niche. In addition, reserve stem-like cells and/or
more mature cell types can assume the stem cell mantle and replenish the injured epithelium, if
LGR5+ stem cell function is compromised. Here, we discuss the niche signals that govern the stem
cell state, and how these go awry in the development of colorectal cancer.
Abstract: The intestinal epithelium fulfils pleiotropic functions in nutrient uptake, waste elimination,
and immune surveillance while also forming a barrier against luminal toxins and gut-resident mi-
crobiota. Incessantly barraged by extraneous stresses, the intestine must continuously replenish its
epithelial lining and regenerate the full gamut of specialized cell types that underpin its functions.
Homeostatic remodelling is orchestrated by the intestinal stem cell (ISC) niche: a convergence of
epithelial- and stromal-derived cues, which maintains ISCs in a multipotent state. Following demise
of homeostatic ISCs post injury, plasticity is pervasive among multiple populations of reserve stem-
like cells, lineage-committed progenitors, and/or fully differentiated cell types, all of which can
contribute to regeneration and repair. Failure to restore the epithelial barrier risks seepage of toxic
luminal contents, resulting in inflammation and likely predisposing to tumour formation. Here, we
explore how homeostatic niche-signalling pathways are subverted in tumorigenesis, enabling ISCs
to gain autonomy from niche restraints (“ISC emancipation”) and transform into cancer stem cells
capable of driving tumour initiation, progression, and therapy resistance. We further consider the im-
plications of the pervasive plasticity of the intestinal epithelium for the trajectory of colorectal cancer,
the emergence of distinct molecular subtypes, the propensity to metastasize, and the development of
effective therapeutic strategies.
Keywords: intestinal stem cells (ISCs); intestinal stem cell (ISC) niche; colorectal cancer (CRC); cancer
stem cells (CSCs); consensus molecular subtypes (CMS); Wnt; Notch; BMP; YAP; regeneration
1. Introduction
The single-layer epithelium lining the intestinal tract is integral to its functions in water
and nutrient absorption, waste elimination, and immune surveillance while also forming
a barrier against luminal toxins and gut-resident microbiota. To weather the barrage
of chemical, pathogenic, and mechanical stresses posed by the digestive process, and
counterbalance cell attrition, the intestine must continuously replenish its epithelial lining
and regenerate the full gamut of specialized cell types that underpin its diverse functions.
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The homeostatic renewal of this epithelium is critically dependent on the sustained activity
of multipotent intestinal stem cells (ISCs), residing within submucosal invaginations, called
crypts. ISCs can self-renew while also giving rise to short-lived transit-amplifying (TA)
cells, which in turn undergo successive rounds of cell division to generate multiple mature
intestinal cell types (Figure 1). Broadly, differentiated intestinal cell lineages are specialized
to perform either absorptive or secretory functions [1]. Absorptive enterocytes retrieve
nutrients and water from luminal contents, whereas rare microfold (M) cells function
in immune surveillance, delivering luminal antigens to underlying lymphoid structures
(Peyer’s patches). Secretory lineages include multiple hormone- and neurotransmitter-
secreting enteroendocrine cell types that regulate physiological responses to food intake and
interface with the enteric nervous system, mucus-secreting goblet cells that fortify the host
epithelium against mechanical stresses and luminal microorganisms, and chemosensory
tuft cells that orchestrate type-2 immunity responses to helminth parasites and allergens [1].
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Figure 1. The architecture of the small intestine and the colon. Schematic depicting a longitudinal section of the intestinal 
mucosa. The mucosa of the small intestine extends finger-like projections (villi) into the gut lumen, which provide an 
increased surface area for optimal nutrient absorption. The villi are populated by mature, differentiated absorptive and 
secretory cell types, including absorptive enterocytes, hormone- and neurotransmitter-secreting enteroendocrine cells, 
mucus-secreting goblet cells, tuft cells, and microfold (M) cells (not shown). The mucosa surrounding the villi forms tub-
ular invaginations into the lamina propria, called crypts, which serve as a protected reservoir of stem and progenitor cell 
populations. Notably, the epithelium of the colon is devoid of villi, with the crypts opening onto a flat mucosal surface, 
reflecting its role in waste compaction. To support homeostatic turnover, ISCs self-renew and give rise to short-lived 
transit-amplifying (TA) cells, which in turn beget lineage-restricted progenitors that differentiate into the mature cell types 
lining the villi. During their limited lifespan, intestinal epithelial cells migrate from the base of the crypt to the tip of the 
villus or the colonic surface, from where they are shed into the gut lumen and replaced by neighbouring cells. In contrast, 
Paneth cells are relatively long-lived, and migrate to the base of the crypt, where they secrete antimicrobial peptides and 
form a vital component of the ISC niche. Paneth cells are absent from the colon, but deep crypt secretory (DCS) cells may 
fulfil an equivalent role. Opposing gradients of morphogens specify intestinal-cell fate and differentiation along the ver-
tical crypt axis: Wnt and Notch signalling prevail at the crypt base, whereas BMP transduction is highest near the lumen. 
Since aberrant ISC proliferation or, conversely, the failure to mobilize ISCs in re-
sponse to injury is invariably detrimental, ISC activity is kept in check by the local milieu: 
the ISC niche. Set within the confines of the crypt base, the ISC niche is comprised of either 
Paneth cells in the small intestine or deep crypt secretory (DCS) cells in the colon, in ad-
dition to pericryptal fibroblasts, immune cells, endothelial cells, enteric neurocytes, extra-
cellular matrix (ECM) components, and soluble cytokines and growth factors. Multiple 
Figure 1. The architecture of the small intestine and the colon. Schematic epicting a longitudinal
secti n of the intes inal mucosa. The mucosa of the small intest e ext nds finger-like projections
(villi) into the gut lumen, which provide an increased surface area for optimal nutrient absorption.
The villi are populated by mature, differentiated absorptive and secretory cell types, including
absorptive enterocytes, hormone- and neurotransmitter-secreting enteroendocrine cells, mucus-
secreting goblet cells, tuft cells, and microfold (M) cells (not shown). The mucosa surrounding the
villi forms tubular invaginations into the lamina propria, called crypts, which serve as a protected
reservoir of stem and progenitor cell populations. Notably, the epithelium of the colon is devoid of
villi, with the crypts opening onto a flat mucosal surface, reflecting its role in waste compaction. To
support homeostatic turnover, ISCs self-renew and give rise to short-lived transit-amplifying (TA)
cells, which in turn beget lineage-restricted prog nitors that differ ntiate into the mature cell typ
lining the villi. During their limited lifespan, intestinal epithelial cells migrate from the base of the
crypt to the tip of the villus or the colonic surface, from where they are shed into the gut lumen and
replaced by neighbouring cells. In contrast, Paneth cells are relatively long-lived, and migrate to
the base of the crypt, where they secrete antimicrobial peptides and form a vital component of the
ISC niche. Paneth cells are absent from the colon, but deep crypt secretory (DCS) cells may fulfil an
equivalent role. Opposing gradients of morphogens specify intestinal-cell fate and differentiation
along the vertical crypt axis: Wnt and Notch signalling prevail at the crypt base, whereas BMP
transduction is highest near the lumen.
Since aberrant ISC proliferation or, conversely, the failure to mobilize ISCs in response
to injury is invariably detrimental, ISC activity is kept in check by the local milieu: the
ISC niche. Set within the confines of the crypt base, the ISC niche is comprised of either
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Paneth cells in the small intestine or deep crypt secretory (DCS) cells in the colon, in
addition to pericryptal fibroblasts, immune cells, endothelial cells, enteric neurocytes,
extracellular matrix (ECM) components, and soluble cytokines and growth factors. Multiple
converging niche-signalling pathways—primarily Wnt, Notch, and BMP—maintain ISCs
in a multipotent state and fine-tune the balance between self-renewal and differentiation.
Due to the intricate three-dimensional structure of the intestinal crypt (Figure 1),
resolving the nuances of the ISC niche using traditional two-dimensional cell cultures is
impracticable. However, recent advances in transgenic animal modelling—particularly cell
fate-mapping and lineage tracing—and the advent of organoid technologies and single-cell
transcriptomics have illuminated the molecular mechanisms governing ISC behaviour.
Here, we discuss the signalling pathways that constitute the ISC niche, and how their
subversion may lead to what we term “ISC emancipation”, whereby ISCs gain autonomy
from the niche. ISC emancipation arises when a mutation either negates ISC dependence on
pro-proliferative and pro-survival niche signals, or enables ISCs to evade growth-inhibitory
stimuli, permitting unbridled expansion of stem-like populations that spur tumour growth.
Furthermore, we discuss emerging therapeutic approaches to curtail ISC emancipation and
consider the implications of the pervasive plasticity of the intestinal epithelium for tumour
initiation, progression, and treatment.
2. ISCs in a Nutshell
Daily homeostatic turnover of the intestinal epithelium is orchestrated by crypt-base
columnar cells, nestled between either Paneth or DCS cells at the crypt base in the small
intestine and colon, respectively [2,3]. Decorated with the RSPO-receptor LGR5, which
potentiates canonical Wnt/β-catenin signalling [4–6], these highly proliferative cells (here-
after Lgr5+ ISCs) exhibit the ability to self-renew and differentiate into all intestinal lineages
in vitro and in vivo [7,8] and are tasked with the homeostatic renewal of the epithelium
in both the small intestine and the colon [7] (Figure 2a). Yet, remarkably, the adult in-
testinal epithelium can fully recover following acute ablation of Lgr5-expressing cells [9],
and conditional deletion of the Lgr5 gene does not visibly perturb crypt architecture [4].
Together, these findings bring forth the redundancy of Lgr5+ ISCs for homeostasis and
suggest that other cell types can compensate for their deficiency in this setting. Neverthe-
less, sustained depletion of Lgr5+ ISCs severely compromises the regenerative response to
radiation-induced damage [10], suggesting that any compensatory cell types, deployed
post injury, must first repopulate the Lgr5+ compartment prior to reconstituting the lost
epithelium. Indeed, multiple putative reserve ISC pools have been proposed to reside
just above the crypt base—around the so-called +4 position—based on DNA-label re-
tention [11] and lineage tracing with eGFP−IRES−CreER reporters inserted into the loci
encoding BMI1 [12], mTERT [13], HOPX [14], or LRIG1 [15]. These slow-cycling reserve
populations can be mobilized post injury to replenish lost or damaged Lgr5+ ISCs [9,12–19].
In addition, multiple lineage-committed progenitors and fully differentiated cell types
can dedifferentiate and regain stem-like traits. Notably, Alpi+ enterocyte precursors [20],
Prox1+ enteroendocrine-lineage cells co-expressing tuft-cell markers [21] and other sub-
sets of enteroendocrine cells [22–24], CD69+CD274+ goblet cell precursors [25], secretory
progenitors expressing Dll1 [26] or Atoh1 (also known as Math1) [27–30], differentiated
KRT20+ surface enterocytes in the colon [31], as well as post-mitotic tuft [32], enterochro-
maffin [33], and Paneth cells [34–36] can contribute to varying degrees to crypt homeostasis
and injury-induced regeneration (Figure 2b).
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Figure 2. Cellular hierarchies and phenotypic plasticity in the intestinal epithelium during homeostasis, post-injury re-
generation, and tumorigenesis. The dendrograms summarize key lineage relationships between Lgr5⁺ ISCs, transit-ampli-
fying (TA) cells, lineage-committed precursors, terminally differentiated intestinal cell types, +4/reserve ISCs, and revival 
stem cells in different settings. (a) The homeostatic remodelling of the intestinal epithelium is orchestrated by niche signals 
that fine-tune the balance between Lgr5⁺ ISC self-renewal and differentiation. Revival stem cells are rare under homeostatic 
conditions (dashed boundary), and +4/reserve ISCs contribute only weakly to daily turnover during homeostasis (double-
headed dashed arrow). (b) Following ablation of Lgr5⁺ ISCs post injury, +4/reserve ISCs can mobilize to replenish lost Lgr5⁺ 
ISCs and repopulate damaged crypts. Differentiated Lgr5⁺ progeny upregulate Clu in a YAP1-dependent manner, transi-
ently serving as revival stem cells that can generate Lgr5⁺ ISCs de novo. Lineage-committed precursors and/or fully dif-
ferentiated cells can dedifferentiate, revert to an Lgr5⁺ state, and regain stem-like traits. The transcription factor ASCL2 is 
critical for the ability of recent Lgr5⁺ ISC progeny to undergo dedifferentiation to an Lgr5⁺ state. Of note, Clu⁺ cells are 
distinct from the Lgr5⁺ and Ascl2⁺ populations. (c) Aberrant activation of Wnt signalling drives unbridled proliferation of 
Lgr5⁺ ISCs leading to intestinal hyperplasia. TA and differentiated cells, with hyperactive Wnt signalling and mutant 
KRASG12D, may progress to malignancy in the context of TGFβ-receptor loss or inflammation (i.e., NFκB activation). Mul-
tiple +4/reserve ISCs can also initiate tumorigenesis, and tuft cells are readily transformed by inflammation following Apc 
loss. Whether revival stem cells can serve as tumour-initiating cells remains unclear. Solid arrows indicate the ability to 
dedifferentiate and revert to a stem-like state, or the susceptibility to transformation and hyperplastic progression. Reflex-
ive arrows indicate the ability to self-renew. Double-headed solid arrows denote dynamic interconversion between indi-
cated cell types. Note that, to date, goblet cell progenitors have not been lineage-traced. 
Recent insights have also highlighted heterogeneity within the Lgr5⁺ compartment 
itself. Addressing a long-standing controversy in the field, Buczacki and colleagues iden-
tified label-retaining cells as Lgr5⁺eGFPhi secretory precursors of Paneth and enteroendo-
crine cells that do not contribute to homeostasis [30] and are discrete from the +4/reserve 
ISCs marked by CreER knock-in reporters [42]. Two additional slow-cycling Lgr5⁺ ISC sub-
populations, expressing Mex3a [43] or Krt15 [44], were found to survive genotoxic stress 
and contribute to radiation-induced regeneration. In this respect, these slow-cycling Lgr5⁺ 
ISC subsets exhibit purported traits of +4/reserve ISCs and markedly contrast with the 
highly proliferative, radio-sensitive Lgr5⁺ ISC population. Furthermore, a rapidly-cycling, 
DNA damage-resistant subpopulation of Msi1⁺ cells, that expresses little-to-no Lgr5 and 
resides at the +4 position, has recently been shown to repopulate the intestinal epithelium 
post irradiation [45]. Crucially, Msi1⁺ cells are mobilized before the reappearance of Lgr5⁺ 
cells, challenging the widely held contention that +4/reserve ISCs must regain Lgr5 ex-
pression prior to instigating repair [46]. Although able to repopulate all major intestinal 
lineages, Msi1⁺ cells preferentially differentiate into Paneth cells, suggesting that they may 
first replenish the ISC niche to help restore Lgr5⁺ ISC functionality in the newly 
Figure 2. Cellular hierarchies and phenotypic plasticity in the intestinal epithelium during homeostasis, post-injury
regeneration, and tumorigenesis. The dendrograms summarize key lineage relationships between Lgr5+ ISCs, transit-
amplifying (TA) cells, lineage-committed precursors, terminally differentiated intestinal cell types, +4/reserve ISCs, and
revival stem cells in different settings. (a) The homeostatic remodelling of the intestinal epithelium is orc estrated by
niche signals t at fine-tune the balanc between Lgr5+ ISC self-renewa and d fferentiation. Revival stem cells are rare
un r homeost tic conditions (dashed boundary), and +4/re erve ISCs contribute only weakly to daily turnover during
homeostasis (double-headed dashed arrow). (b) Following ablation of Lgr5+ ISCs post injury, +4/reserve ISCs can mobilize
to replenish lost Lgr5+ ISCs and repopulate damaged crypts. Differentiated Lgr5+ progeny upregulate Clu in a YAP1-
dependent manner, transiently serving as revival stem cells that can generate Lgr5+ ISCs de novo. Lineage-committed
precursors and/or fully differentiated cells can dedifferentiate, revert to an Lgr5+ state, and regain stem-like traits. The
transcription factor ASCL2 is critical for the ability of recent Lgr5+ ISC progeny to undergo dedifferentiation to an Lgr5+
state. Of note, Clu+ cells are distinct from the Lgr5+ and Ascl2+ populations. (c) Aberrant activation of Wnt signalling
drives unbridled proliferati n of Lgr5+ ISCs leading to intestinal hyperplasia. TA and differentiated cells, with hyperactive
Wnt signalling and mutant KRASG12D, may progress to malignancy in the context of TGFβ-receptor loss or inflammation
(i.e., NFκB ctivation). Multiple +4/reserve ISCs can also initiate tumorigenesis, a d tuft cells are readily transformed by
inflammation following Apc loss. Whether revival stem cells can serve as tumour-initiating cells remains unclear. Solid
arrows indicate the ability to dedifferentiate and revert to a stem-like state, or the susceptibility to transformation and
hyperplastic progression. Reflexive arrows indicate the ability to self-renew. Double-headed solid arrows denote dynamic
interconversion between indicated cell types. Note that, to date, goblet cell progenitors have not been lineage-traced.
Classific tio of ISCs is further confounded by the expressio of mark rs of +4/re-
serve ISCs (Bmi1, mTert, Hopx, Lrig1) in Lgr5+ cells, suggesting considerable overlap
between these populati ns [37–39]. Indeed, Lgr5+ and +4/reserve ISCs can dynami-
cally interconvert during both homeostatic and radiation-i uced regenerati n, although
+4/reserve ISCs contribute only weakly to daily turnover under non-pathological condi-
tion [9,14,16,17]. Neverthel ss, mo t +4/res rve ISC populations (inc uding Dll+ secretory
precursors) differ profoundly from Lgr5+ s as they are rela ively refractory to Wnt stim-
ulation, lack xpression of canonical Wnt-target g nes, and exhibit res stance t hi h-dose
irradiation [14,16,17,40,41].
Recen insights have lso highlighted heterogeneity within the Lgr5+ compartment
itself. Addressing a long-standing controversy in the field, Buczacki and colle gues identi-
fi d label-retaining cells as Lgr5+eGFPhi secret ry precurs rs of Paneth and enteroe docrine
cells that do not contribute to homeostasis [30] and are discrete from the +4/reserve ISCs
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marked by CreER knock-in reporters [42]. Two additional slow-cycling Lgr5+ ISC subpopu-
lations, expressing Mex3a [43] or Krt15 [44], were found to survive genotoxic stress and
contribute to radiation-induced regeneration. In this respect, these slow-cycling Lgr5+ ISC
subsets exhibit purported traits of +4/reserve ISCs and markedly contrast with the highly
proliferative, radio-sensitive Lgr5+ ISC population. Furthermore, a rapidly-cycling, DNA
damage-resistant subpopulation of Msi1+ cells, that expresses little-to-no Lgr5 and resides
at the +4 position, has recently been shown to repopulate the intestinal epithelium post
irradiation [45]. Crucially, Msi1+ cells are mobilized before the reappearance of Lgr5+ cells,
challenging the widely held contention that +4/reserve ISCs must regain Lgr5 expression
prior to instigating repair [46]. Although able to repopulate all major intestinal lineages,
Msi1+ cells preferentially differentiate into Paneth cells, suggesting that they may first
replenish the ISC niche to help restore Lgr5+ ISC functionality in the newly remodelled
crypt [45]. An additional distinct—but transient—population comprises the immediate
progeny of Lgr5+ ISCs, expressing modestly reduced levels of ISC-associated transcripts
alongside markers of mature secretory cells and enterocytes [47]. An example of multilin-
eage gene priming, this transient bipotential progenitor population is poised to lose Lgr5
expression entirely as cells move further from the crypt base along their ultimate cell-fate
trajectory [47,48]. Collectively, these findings suggest considerable overlap and dynamic
interconversions between crypt ISC populations and implicate the local niche as the main
“influencer” of stem-like behavioural and phenotypic traits.
Bringing a long-standing debate to an apparent close [49], recent studies have at-
tributed the bulk of intestinal epithelial regeneration to the dedifferentiation of recent
progeny of Lgr5+ ISCs. Both absorptive and secretory cell lineages are recruited to replen-
ish the stem-cell pool post injury, with the underlying kinetics precluding the mobilization
and expansion of dedicated reserve ISC populations [50]. Mechanistically, such pervasive
dedifferentiation is underpinned by a permissive open chromatin configuration in progeni-
tor cells undergoing differentiation [51], with only incremental chromatin remodelling of
lineage-restricted genes required to interconvert between homeostatic Lgr5+ ISCs and their
secretory and absorptive eventual progeny during differentiation, and vice versa during
crypt regeneration [25,51].
While at times confounding, these studies collectively converge on the fact that most,
if not all, crypt-resident cell types display phenomenal plasticity and retain (dormant)
stemness potential, calling into question the existence of a “dedicated” reserve ISC pool.
Importantly, they underscore the notion that stemness is not a cell-intrinsic trait and refocus
attention on the role of the niche in governing ISC function during homeostasis and the de
novo acquisition of stemness in times of stress.
3. Principal Niche-Signalling Pathways
Isolated Lgr5+ ISCs cultured in Matrigel supplemented with mesenchymal-derived
growth factors—namely, the mitogen EGF, the Wnt agonist RSPO, and the BMP inhibitor
NOG—can generate organoids that recapitulate the polarity, organization, and cellularity
of the crypt–villus configuration [8]. Nevertheless, co-cultured Paneth cells significantly
augment organoid-forming efficiency [52], hinting at a more complex interplay of epithelial
and mesenchymal components in the niche in vivo. Indeed, the balance between ISC self-
renewal and differentiation in vivo is tightly regulated through the integration of multiple
epithelial- and stromal-derived cues, with primary signalling inputs from the Wnt, Notch,
and BMP pathways (Figures 1 and 3).




Figure 3. Principal niche-signalling pathways in small-intestinal homeostasis. The schematic represents LGR5⁺ ISCs within 
the niche at the crypt base, flanked by Paneth cells (centre) and pericryptal fibroblasts. Key components of the Wnt, Notch, 
BMP, and EGF pathways are indicated. Paneth cells present membrane-bound Notch ligands (DLLs) and secrete WNT3, 
WNT6, WNT9B, and EGF, as well as antimicrobials and lactate (not shown). Multiple pericryptal fibroblast populations 
differentially secrete agonists and antagonists of key niche pathways along the vertical crypt axis. Upper right: In the ab-
sence of RSPO-binding, the WNT-receptors FZDs (FZD1–10) are targeted for degradation by the E3-ubiquitin ligases 
RNF43 and ZNRF3. Furthermore, the Wnt antagonists SFRPs (SFRP1–5) and WIF1 sequester secreted WNT ligands, 
whereas DKKs (DKK1–4) bind to the LRP5/6 receptors, preventing WNT-ligand binding. Consequently, cytoplasmic β-
catenin is bound by the scaffolding proteins APC and Axin-2, and sequentially phosphorylated by the kinases CK1 and 
GSK3β, marking it for proteasomal degradation. Lower right: RSPOs (RSPO1–4) bind the LGR-family of receptors (LGR4–
6) and potentiate canonical Wnt signalling by inhibiting the degradation of FZDs by RNF43 and ZNRF3. Upon binding of 
WNT ligands to their cognate FZD and LRP co-receptors, DVL and Axin-2 are recruited to the membrane, triggering the 
phosphorylation of LRP5/6 by GSK3β. This, in turn, culminates in the dissociation of the destruction complex, leading to 
stabilization of β-catenin and its translocation to the nucleus, where it drives LEF/TCF-dependent transactivation of Wnt-
target genes. Lower left and middle: Binding of Notch ligands (DLL1, DLL4), on the surface of Paneth cells, to juxtaposed 
Notch receptors (NOTCH1, NOTCH2) of adjacent LGR5⁺ ISCs triggers the proteolytic release of NICD, resulting in Notch-
pathway activation in LGR5⁺ ISCs and its suppression in Paneth cells. As a result, the transcriptional repressor HES1 is 
activated in LGR5⁺ ISCs and ISC-associated markers are transcribed. In Paneth cells, the transcription factor MATH1 en-
hances DLL expression, and WNT/FZD5 transduction drives SOX9-dependent differentiation and expression of Wnt-tar-
get genes (AXIN2, SOX9) but not stemness genes (ASCL2, LGR5). Upper left: Binding of EGF to EGFR activates multiple 
downstream signalling cascades, including the RAS/BRAF/MEK/ERK and PI3K/AKT pathways which promote prolifera-
tion and survival, respectively. Inset: BMP activity forms a decreasing gradient from the intestinal lumen to the crypt base. 
Near the lumen, BMP signal transduction is initiated upon the binding of BMP ligands to their cognate BMPR receptors, 
leading to phosphorylation of R-SMADs, formation and nuclear translocation of R-SMAD/SMAD4 complexes, and trans-
activation of target genes involved in differentiation, cell-cycle withdrawal, and apoptosis. At the crypt base, pericryptal 
stromal cells secrete BMP antagonists (GREM1, CHDL1), protecting ISCs and progenitors from the cytostatic effects of 
BMPs. Infiltrating immune cells, endothelial cells, enteric neurocytes, and ECM components that also contribute to the 
niche are not shown. Solid arrows indicate direct activation, dashed arrows signify multiple intermediary steps, lines 
ending with a bar denote inhibition, grey colouring indicates suppression/inactivation, and circled P indicates phosphor-
ylation. 
RSPOs (RSPO1–4) bind the LGR family of receptors (LGR4–6) and potentiate canon-
ical Wnt signalling by inhibiting the degradation of the WNT-receptors, FZDs (FZD1–10), 
by the E3-ubiquitin ligases RNF43 and ZNRF3 [4,6,64,65]. While WNTs and RSPOs syn-
ergize to augment Wnt signalling, they each serve distinct roles within the niche. Notably, 
WNT ligands alone cannot evoke Lgr5⁺ ISC self-renewal; instead, they maintain basal 
RSPO-receptor (Lgr5, Rnf43, Znrf3) expression, priming Lgr5⁺ ISCs for RSPO-driven 
Figure 3. Principal niche-signalling pathways in small-intestinal homeostasis. The schematic represents LGR5+ ISCs within
the niche at the crypt base, flanked by Paneth cells (centre) and pericryptal fibroblasts. Key components of the Wnt, Notch,
BMP, and EGF pathways are indicated. Paneth cells present membrane-bound Notch ligands (DLLs) and secrete WNT3,
WNT6, WNT9B, and EGF, as well as antimicrobials and lactate (not shown). Multiple pericryptal fibroblast populations
differentially secrete agonists and antagonists of key niche pathways along the vertical crypt axis. Upper right: In the absence
of RSPO-binding, the WNT-receptors FZDs (FZD1–10) are targeted for degradation by the E3-ubiquitin ligases RNF43 and
ZNRF3. Furthermore, the Wnt antagonists SFRPs (SFRP1–5) and WIF1 sequester secreted WNT ligands, whereas DKKs
(DKK1–4) bind to the LRP5/6 receptors, preventing WNT-ligand binding. Consequently, cytoplasmic β-catenin is bound
by the scaffolding proteins APC and Axin-2, and sequentially phosphorylated by the kinases CK1 and GSK3β, marking it
for proteasomal degradation. Lower right: RSPOs (RSPO1–4) bind the LGR-family of receptors (LGR4–6) and potentiate
canonical Wnt signalling by inhibiting the degradation of FZDs by RNF43 and ZNRF3. Upon binding of WNT ligands to
their cognate FZD and LRP co-receptors, DVL and Axin-2 are recruited to the membrane, triggering the phosphorylation
of LRP5/6 by GSK3β. This, in turn, culminates in the dissociation of the destruction complex, leading to stabilization of
β-catenin and its translocation to the nucleus, where it drives LEF/TCF-dependent transactivation of Wnt-target genes.
Lower left and middle: Binding of Notch ligands (DLL1, DLL4), on the surface of Paneth cells, to juxtaposed Notch receptors
(NOTCH1, NOTCH2) of adjacent LGR5+ ISCs triggers the proteolytic release of NICD, resulting in Notch-pathway activation
in LGR5+ ISCs and its suppression in Paneth cells. As a result, the transcriptional repressor HES1 is activated in LGR5+ ISCs
and ISC-associated markers are transcribed. In Paneth cells, the transcription factor MATH1 enhances DLL expression, and
WNT/FZD5 transduction drives SOX9-dependent differentiation and expression of Wnt-target genes (AXIN2, SOX9) but
not stemness genes (ASCL2, LGR5). Upper left: Binding of EGF to EGFR activates multiple downstream signalling cascades,
including the RAS/BRAF/MEK/ERK and PI3K/AKT pathways which promote proliferation and survival, respectively.
Inset: BMP activity forms a decreasing gradient from the intestinal lumen to the crypt base. Near the lumen, BMP signal
transduction is initiated upon the binding of BMP ligands to their cognate BMPR receptors, leading to phosphorylation
of R-SMADs, formation and nuclear translocation of R-SMAD/SMAD4 complexes, and transactivation of target genes
involved in differentiation, cell-cycle withdrawal, and apoptosis. At the crypt base, pericryptal stromal cells secrete BMP
antagonists (GREM1, CHDL1), protecting ISCs and progenitors from the cytostatic effects of BMPs. Infiltrating immune cells,
endothelial cells, enteric neurocytes, and ECM components that also contribute to the niche are not shown. Solid arrows
indicate direct activation, dashed arrows signify multiple intermediary steps, lines ending with a bar denote inhibition, grey
colouring indicates suppression/inactivation, and circled P indicates phosphorylation.
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Wnt signalling has long been implicated in the maintenance of intestinal homeostasis
and ISC function. In the absence of Wnt signalling, cytoplasmic β-catenin is targeted
for degradation by the APC-dependent destruction complex. Binding of WNT ligands
to their cognate FZD and LRP co-receptors dissociates the destruction complex and pro-
motes nuclear translocation of β-catenin, driving LEF/TCF-dependent transactivation of
Wnt-target genes (e.g., Myc, Ccnd1) (Figure 3). Genetic deletion of various Wnt-pathway
components results in crypt ablation, ISC differentiation, and depletion of secretory lin-
eages [53–58], underscoring the crucial role of this pathway in intestinal homeostasis.
Conversely, APC-deficient Lgr5+ ISCs drive rapid adenoma formation in the mouse small
intestine [59]. Indeed, aberrant Wnt signalling underpins colorectal cancer (CRC) initiation
and progression in humans, with loss-of-function mutations in the APC tumour suppressor
gene reported in >80% of sporadic cases and germline mutations predisposing to famil-
ial adenomatous polyposis [60]. Notably, tumorigenesis selects for APC mutants with a
residual ability to downregulate β-catenin [61] and, furthermore, the spectrum of APC
mutations in tumours varies along the length of the intestine, reflecting local variations in
Wnt-signal strength [62]. Thus, a “just-right” level of Wnt activity sustains growth of early
dysplastic lesions [61] and promotes mutant fixation [63], whereas over-activation of Wnt
signalling elicits apoptosis and counters polyp formation [61].
RSPOs (RSPO1–4) bind the LGR family of receptors (LGR4–6) and potentiate canonical
Wnt signalling by inhibiting the degradation of the WNT-receptors, FZDs (FZD1–10), by
the E3-ubiquitin ligases RNF43 and ZNRF3 [4,6,64,65]. While WNTs and RSPOs synergize
to augment Wnt signalling, they each serve distinct roles within the niche. Notably, WNT
ligands alone cannot evoke Lgr5+ ISC self-renewal; instead, they maintain basal RSPO-
receptor (Lgr5, Rnf43, Znrf3) expression, priming Lgr5+ ISCs for RSPO-driven proliferative
expansion. Thus, RSPOs maintain Lgr5+ ISCs in a multipotent, undifferentiated state
and, crucially, control the size of the Lgr5+ ISC pool in a Wnt-dependent manner [66].
Independently of LGR5, however, a recent study identified an important role for stromal
RSPO3 in orchestrating the colonic wound-healing response to treatment with dextran
sodium sulphate (DSS), a widely used chemical colitogen that acutely damages the colonic
mucosa [67–69]. Here, RSPO3 reprograms Lgr5−Lgr4+ differentiated cells (by engaging the
RSPO3-receptor LGR4) into a Wnt-high, stem-like state, capable of supporting epithelial
regeneration following DSS-induced Lgr5+ ISC depletion [31]. These data suggest that a
rewired niche interactome may instruct cell fate during tissue distress.
In homeostasis, canonical Wnt activity prevails at the crypt base and the associated
target-gene expression declines as cells ascend the vertical crypt axis [70]. In addition to
Lgr5—itself a Wnt-target gene—Lgr5+ ISCs express other Wnt targets, including Ascl2, Sox9,
Troy, and Axin2 [39,71,72], underscoring the importance of Wnt signalling for safeguarding
the stem cell state at the crypt base [72]. ASCL2—a master regulator of the Lgr5+ ISC
gene expression program—perpetuates its own expression in a positive feedback loop,
controlled by WNT/RSPO levels. Thus, while an “Ascl2-on” state imparts stemness, “Ascl2-
off” cells are destined to differentiate, with the corollary that TA cells can regain stemness
upon encountering increased WNT/RSPO levels sufficient to drive Ascl2 expression [73].
In fact, the induction of Ascl2 is critical for the ability of recent Lgr5+ ISC progeny to
undergo dedifferentiation to an Lgr5+ state prior to regenerating the injured intestinal
epithelium [50].
The Notch pathway also regulates the proliferation and multipotency of Lgr5+ ISCs,
while additionally specifying TA cell fate [74–76]. Briefly, binding of transmembrane Notch
ligands (DLL1, DLL4, JAG1, JAG2) to juxtaposed Notch receptors (NOTCH1, NOTCH2) of
adjacent cells results in Notch-pathway suppression in the signal-sending cell and activa-
tion in the receiving cell, a process known as lateral inhibition [77]. The NOTCH receptor
is proteolytically cleaved by γ-secretase, liberating its transcriptionally active intracellular
domain (NICD), which converges with the coactivator RBPJ to drive Notch target-gene
expression (Figure 3). In the TA-cell compartment, abrogation of Notch signalling enforces
differentiation of proliferative cells into secretory cells via recruitment of MATH1, the mas-
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ter regulator of secretory fate [74,78,79]. Conversely, constitutive Notch signalling activates
the transcriptional repressor, HES1, prompting a switch to an enterocyte fate [75,76,80,81].
The constitutively activated Notch phenotype is also notable for the marked expansion
of crypt progenitors, implicating Notch signalling in this compartment [75]. Consistent
with this notion, the NOTCH1 and NOTCH2 receptors are restricted to Lgr5+ ISCs, whereas
the instructive Notch ligands DLL1 and DLL4 are expressed on Paneth cells in the small
intestine [52,82] or DCS cells in the colon [3]. Moreover, activity of the Notch-effector
HES1 is detected in Lgr5+ ISCs as well as absorptive progenitors [52,83]. Accordingly,
simultaneous deletion of Dll1 and Dll4, or pharmacological inhibition of Notch, elicits the
conversion of proliferative Lgr5+ ISCs into post-mitotic goblet cells, concomitant with loss
of ISC-associated markers (e.g., Lgr5, Olfm4, and Ascl2) [82,84]. Conversely, constitutive
activation of Notch signalling in Paneth cells prompts their dedifferentiation into a stem-like
Lgr5+ state [35,36]. These findings underscore the requirement of Notch signalling for the
survival, maintenance, and activity of the Lgr5+ ISC pool as well as for cell-fate decisions.
Moreover, whereas secretory lineage commitment requires MATH1, transcription of the ISC
marker and Notch target, Olfm4, requires RBPJ and occurs independently of MATH1 [84],
implicating distinct downstream Notch-effector pathways in cell-fate specification and
ISC maintenance.
BMP activity counters Wnt signalling, forming a decreasing gradient from the intesti-
nal lumen to the crypt base [70,85] (Figures 1 and 3). BMP signal transduction is initiated
upon binding of BMP ligands to their cognate BMP-receptors (BMPRs), leading to phospho-
rylation of R-SMADs (SMAD1, SMAD5, SMAD8), formation and nuclear translocation of
R-SMAD/SMAD4 complexes, and transactivation of target genes [86]. BMP ligands (BMP2,
BMP4) abound near the lumen, promoting cell-cycle withdrawal, differentiation, and apop-
tosis of luminal epithelial cells [85,87,88]. Conversely, at the crypt base, pericryptal stromal
cells secrete the BMP antagonists GREM1, GREM2, and NOG, which sequester the BMP
ligands away from their cognate receptors, thereby protecting ISCs and progenitors from
the cytostatic effects of BMPs [70,88–92]. Accordingly, acute Grem1 deletion precipitates a
severe enteropathy with profound tissue atrophy, consistent with the demise of prolifera-
tive Lgr5+ ISCs [93]. On the other hand, aberrant expression of Grem1 [94] or Nog [87] in the
mouse intestinal epithelium severely disrupts BMP-morphogen gradients, leading to the
formation of ectopic crypts and polyps with a pathology reminiscent of human polyposis
syndromes [87,94,95], typically associated with mutations in BMP-pathway genes and a
high-risk predisposition to CRC [96]. Similarly, simultaneous deletion of Bmpr1a in the
stromal and epithelial compartments yields hyperproliferative crypts that eventually lead
to polyposis [88]. These phenotypes are underpinned by the marked expansion of the
stem/progenitor cell compartment, consistent with a homeostatic role for BMP antagonists
in restricting the self-renewal of Lgr5+ ISCs at the crypt base [87,88,94,95]. Notably, how-
ever, epithelial-specific deletion of Bmpr1a does not elicit de novo crypt formation, thereby
selectively implicating the loss of stromal BMP signalling in the pathology of polyposis [97].
Instead, these mice exhibit increased crypt fission as well as impaired goblet, Paneth, and
enteroendocrine cell maturation, linking epithelial BMP signalling to secretory cell fate [97].
Mechanistically, epithelial BMP signalling selectively drives SMAD/HDAC1-mediated
repression of stem cell-associated genes (e.g., Lgr5, Sox9, Pdgfa, Cdk6, and Cdca7)—notably
without impacting β-catenin nuclear translocation or expression of non-stem canonical
Wnt targets (e.g., Ccnd2, Axin2, and Myc)—thus safeguarding against precocious Lgr5+
ISC expansion and polyp formation in the Wnt-rich niche [95]. Overall, BMP signalling
maintains homeostatic balance by dampening the proliferation of Lgr5+ ISCs at the crypt
base while promoting secretory cell lineage allocation in luminal regions.
Thus, within the confines of the crypt base, Lgr5+ ISCs are nurtured with convergent
niche signals that preserve their self-renewal capabilities and multipotency. But no one
signalling pathway acts in isolation. Below, we touch on the crosstalk between key niche-
signalling pathways and delineate how this shapes an instructive milieu that supports
stemness and dictates cell fate.
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4. Convergence of Niche-Signalling Pathways in Homeostasis
The Wnt and Notch pathways function synergistically to preserve the proliferative
activity and multipotency of Lgr5+ ISCs. According to the emergent model, DLL1+DLL4+
Paneth cells activate Notch signalling in adjacent Lgr5+ ISCs at the crypt base, maintaining
them in an undifferentiated state by tempering Wnt signalling [98] and suppressing secre-
tory lineage specification [82,99]. Additionally, opposing inputs from the Wnt and BMP
pathways control expression of stem-cell-associated signature genes and, consequently,
ISC renewal [70,90,92,95]. EGF is also a major driver of Lgr5+ ISC proliferation, but it is not
linked to stemness potential per se [100]. In fact, Wnt suppresses EGFR/MAPK activity
in vivo to maintain quiescent ISC pools and prevent their premature differentiation into
progenitors [101]. Furthermore, Lgr5+ ISCs themselves secrete the Notch target OLFM4—an
inhibitor of proliferation, inflammation, and Wnt/β-catenin signalling [72,102,103]—and
the BMP inhibitor SMOC2 [39], which in turn likely modulate the niche-signalling output.
Of note, several studies have detected transcripts encoding Wnt antagonists, such
as Axin2, Sfrp1, Sfrp2, Sfrp5, Fzdb, Dkk2, Dkk3, Wif1, and Notum, differentially localized in
crypt epithelial cells or the adjacent mesenchyme [92,104–106]. Whereas these molecules
often have different modes of action and variegated expression patterns, the raison d’être
of so many different Wnt antagonists near the crypt base remains unclear. Their presence,
indeed, points to the need to constantly fine-tune homeostatic Wnt-pathway activity and
ISC function, with the corollary that the breakdown of such negative feedback loops will
likely bear relevance to the emergence of disease. For example, with advancing age, Paneth
cells increasingly secrete NOTUM—a WNT deacylase that disrupts WNT-ligand binding
to FZD receptors [107]—thus limiting the capacity of neighbouring ISCs to self-renew
and regenerate the intestinal epithelium, and compromising intestinal function over the
longer term [106]. Currently in preclinical development, NOTUM inhibitors may therefore
find therapeutic utility in pathologies associated with attenuation of Wnt signalling. For
example, they may be employed to help restore the regenerative capacity of the aging
intestinal epithelium or to ameliorate the ravages of chemotherapy and irradiation [108].
Deciphering the precise target-cell populations of Wnt antagonists deployed within the
niche, how their various modes of action converge or diverge at the crypt base, and how
their functional outputs are altered in regeneration and disease, will better inform our
understanding of crypt dynamics and how to right the balance between self-renewal and
differentiation when gone awry.
Multiple different signals converge to specify lineage choice as cells exit the stem cell
compartment to ascend the crypt. In the TA zone, Notch activity confers an absorptive cell
fate, whereas Delta/Notch lateral inhibition allows secretory commitment. Having lost
contact with Paneth cells, displaced ISCs stochastically begin to express Math1, committing
to a secretory fate as DLL1+DLL4+ progenitors, which subsequently provide instructive
Notch signals to ascending neighbours, fating them toward an enterocyte lineage [26,99].
Concurrent inhibition of Notch, Wnt, and EGFR signalling—which respectively control
enterocyte, Paneth, and goblet cell fates—converts Lgr5+ ISCs into multiple enteroendocrine
subtypes [74,100]. BMP signalling also cooperates with local signals to promote terminal
differentiation of secretory lineages [97].
In the absence of Notch signalling [109], WNT/FZD5 transduction drives SOX9-
dependent maturation of Paneth cells [110–113]. Indeed, mature Paneth cells exhibit active
Wnt/β-catenin signalling and express Wnt-pathway genes (e.g., Axin2, Sox9, Wnt3) but,
notably, lack expression of stemness genes (e.g., Ascl2, Lgr5) [41]. Moreover, Wnt/EphB-
signalling crosstalk ensures correct positioning of Paneth cells at the crypt base [114]. These
findings suggest differential deployment of distinct Wnt-transduction cascades, within the
crypt base, to confer stemness or specify Paneth cell fate. Interestingly, while dramatic loss
of Lgr5+ ISCs upon DSS-driven acute inflammation promotes dedifferentiation and cell-
cycle re-entry of Paneth cells (or their lineage-committed precursors) via the SCF/cKit/Wnt-
signalling axis [34], DNA damage engages the Notch pathway [35,36]. These studies
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suggest that different niche effectors may drive regeneration depending on the mode and
severity of injury [34–36].
In sum, the output of Wnt signalling is fine-tuned by localized concentration gradients
of RSPOs, LGR and FZD receptors [109], Wnt antagonists [104], and components of the
Notch [98], BMP [70,87,88,90], and EGF [100,101] pathways. Below, we discuss the niche
constituent cell types that elaborate these signals.
5. Cellular Circuitries
Paneth cells provide WNT3, WNT6, WNT9B, EGF, Notch ligands, antimicrobials, and
lactate, which sustain the proliferative and metabolic activity of Lgr5+ ISCs [52,104,109,115].
REG4+ DCS cells—purported to be the colonic equivalent of Paneth cells—provide EGF
and the Notch ligands DLL1 and DLL4, enhancing survival of colonic Lgr5+ ISCs in vivo
and in vitro [3,116]. Notably, DCS cells do not secrete canonical WNTs, suggesting the
existence of alternative sources of WNTs in colonic crypts and, likely, accounting for the
dependency of cultured colonic organoids on exogenous WNT3A [117].
Surprisingly, epithelial-specific deletion of Wnt3 [109] or inhibition/deletion of PORCN
(an acyltransferase essential for WNT secretion) [118,119], or Paneth cell ablation [120–122]
does not perturb ISC maintenance, intestinal homeostasis, or radiation-induced regen-
eration. These studies, therefore, concur that epithelial-derived WNTs are redundant in
these settings in vivo. Taken together with the fact that the simultaneous deletion of Wls
in both the epithelial and mesenchymal lineages abrogates WNT secretion and severely
impairs homeostasis [58], these findings contend that crypt-associated stromal cells likely
comprise an important physiological source of Wnt ligands. By contrast, epithelial-derived
WNTs have been ascribed an essential role in mobilizing unharmed Lgr5+ ISCs (but not
+4/reserve ISCs) to replenish differentiated villus epithelial cells, damaged by rotavirus
infection [123]. In this instance, epithelial-specific deletion of the WNT-ligand secretion
mediator, WIs, thwarted the repair process, implicating secreted epithelial-derived WNT
ligands in the recruitment of Lgr5+ ISCs post rotavirus infection [123]. In addition, the
small intestinal epithelium can serve as a compensatory WNT source when WNT secretion
from Gli1+ mesenchymal cells is hindered [124].
Whereas deletion of Porcn in subepithelial myofibroblasts failed to elicit a discernible
phenotype [119], various potentially overlapping pericryptal fibroblast populations, ex-
pressing Foxl1 [89,105], Pdgfrα [125], Gli1 [58,124], or CD34+Gp38+ [91], have been shown
to furnish the niche with abundant WNT ligands. Perturbation of these mesenchymal cell
types (by lineage ablation, or deletion of Porcn or Wls) drastically impaired crypt prolif-
eration in homeostatic and/or pathological settings [58,89,91,124,125]. All these stromal
populations express high levels of WNT2B [58,105], which can rescue Wnt3−/− organoids
from death [109]. Moreover, like WNT3, WNT2B can bind FZD7, a critical receptor for
crypt homeostasis and regeneration [57].
Recent technical advances have illuminated and refined our understanding of how
distinct sub-epithelial stromal populations generate the opposing gradients of Wnt- and
BMP-pathway activity along the crypt–villus axis in the small intestine. Various subpopula-
tions of telocytes—Foxl1+PDGFRα+ subepithelial myofibroblasts so-called after their long
cytoplasmic protrusions (telopodes) that envelop crypt cells—differentially express genes
encoding secreted agonists and antagonists of key niche pathways, including WNT2B,
WNT5A, RSPO3, the Wnt inhibitors DKK3 and SFRP1, various BMPs (BMP4, BMP5, BMP6,
and BMP7), and the BMP inhibitors CHRDL1 and GREM1, providing local positional
cues [105]. For example, Foxl1+PDGFRα+ telocytes express higher levels of Wnt2b and
Rspo3 at the crypt base, stimulating Wnt signalling in apposing Lgr5+ ISCs. Conversely,
transcripts encoding the non-canonical ligand WNT5A, the Wnt antagonists sFRP1 and
DKK3, and BMP5 are enriched near the crypt–villus junction, relaying local differentiation
cues [105].
PDGFRα+ mesenchymal populations have further been subclassified into two dis-
tinctly localized pools, tasked with establishing the diminishing BMP gradient from the
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top to the crypt bottom. First, PDGFRαhi telocytes that predominate at the crypt–villus
junction, as well as the villus tip, supply diffusible BMP agonists luminally, driving lo-
cal cell differentiation [92]. Interestingly, PDGFRαhi telocytes are the only gut-resident
stromal cell known to express BMP7, which is noteworthy given that BMP2/BMP7 and
BMP4/BMP7 heterodimers are significantly more potent signal transducers than their
respective homodimers [92,126]. Second, newly identified CD81+PDGFRαlo subcryptal
trophocytes—named for their ability to support ISC expansion in vitro in the absence of
exogenous factors (i.e., Wnts, RSPOs, and BMP inhibitors)—release the BMP inhibitor
GREM1 at the crypt base, safeguarding the self-renewal capacity of ISCs against diffusible
BMP ligands. These subcryptal trophocytes also secrete RSPO1 and RSPO2 to augment
local Wnt signalling [92]. Dotted among smooth-muscle fibres and running parallel to the
crypt–villus axis, an abundant third population of CD81−PDGFRαlo interstitial fibroblast-
like cells is enriched for Cd34, Pdpn and Gli1 transcripts, and can secrete RSPO1, but its
functional contribution to the niche remains unknown [92].
Intriguingly, a recent study reported the surprising observation that a novel sub-
population of PDGFRα+ telocytes, localized at the villus tip, expresses the crypt stem-cell
marker Lgr5 as well as Rspo3 [127]. Ablation of these Lgr5+ villus-tip telocytes, which also
express Bmp4, Wnt4, Wnt5A, and Egf, profoundly altered the gene-expression profiles of
apposing enterocytes, approaching the villus tip prior to sloughing off into the lumen.
While these results have been met with some scepticism [1,128], any validation of Lgr5+
villus-tip telocytes as a bona fide stromal cell could have far-reaching implications for
approaches relying on Lgr5+ driven Cre-mediated gene targeting or diphtheria toxin-
mediated ablation of cells engineered to express the diphtheria-toxin-receptor, DTR, under
the control of the Lgr5 promoter (Lgr5DTR) [127]. Further studies should interrogate which
Lgr5 transcript variants are expressed in villus-tip telocytes and probe the significance of
their distinctive compartmentalization within telopodes [127]. In addition, such follow-up
studies will need to establish the fidelity of lineage tracing and cell ablation in this model,
given that villus-tip telocytes have been “dismissed” as subcryptal trophocytes [128], and
others have pointed out that tuft cells may also be depleted with this strategy [1].
Collectively, the above studies demonstrate that multiple different cellular circuitries
converge to provide essential—but at times redundant—morphogens to support homeo-
static turnover of the intestinal epithelium.
6. The Immune Niche
Even in homeostatic conditions the intestine is under constant inflammatory assault
from its high microbial load and the influx of dietary antigens. Multiple heterogeneous
populations of long-lived macrophages, residing within discrete niches along the intestinal
tract, differentially display bactericidal activity, help mop up apoptotic debris (efferocyto-
sis), and deploy during wound healing to ensure barrier integrity [129]. In addition to their
roles in immune surveillance and host defence, both gut-resident and tissue-infiltrating
immune cell types have been increasingly recognized as important contributors to the
ISC niche. Notably, antibody-mediated blockade of CSF1R-dependent crypt-associated
macrophages perturbed Paneth cell differentiation, thereby leading to depletion of Lgr5+
ISCs, functional impairment of M cells, and a shift toward goblet cell differentiation [130].
The effects of CSF1R blockade on crypt homeostasis are likely to be two-fold: indirect
by perturbing the differentiation of Paneth cells and direct by depriving Lgr5+ ISCs of
macrophage-produced Wnt4 and Rspo1 [130]. Additionally, post irradiation, gut-resident
macrophages can secrete extracellular vesicles containing WNT5A, WNT6, and WNT9A,
thereby supporting the ensuing regenerative response and augmenting Lgr5+ ISC mobi-
lization [131]. Thus, gut-resident macrophages support crypt homeostasis in the small
intestine and promote mucosal repair post damage, with the corollary that immunogenic
challenge could adversely impact the balance of differentiation in the intestinal epithelium
and, by extension, its functions in immune surveillance. Interestingly, prolonged CSF1R
blockade led to the expansion of SOX9+Bmi1+ cells, demonstrating the mobilization of an
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Lgr5− reserve ISC pool that nevertheless failed to restore the proportions of epithelial cell
lineages in the villus [130].
Aside from macrophages [130,131], innate lymphoid cells have also been shown to
directly influence Lgr5+ ISC function [132,133]. For example, group 3 innate lymphoid cells
and γδ T cells secrete IL22, which induces STAT3 phosphorylation in Lgr5+ ISCs, driving
organoid growth and epithelial regeneration post damage, independently of the Paneth
cell niche [132]. Furthermore, in response to AhR-mediated signalling, IL22 can engage
the DNA-damage response machinery, protecting Lgr5+ ISCs from genotoxic dietary com-
pounds and the acquisition of deleterious mutations [134]. Thus, multiple innate immune
cell types, and the cytokines they produce, play pleiotropic roles within the ISC niche that
go beyond host defence against pathogens to impact ISC fate and differentiation trajectory.
Adaptive immune T cells have also recently emerged as an important determinant
of the ever-pliant immunological milieu [135]. In a landmark study employing single-
cell RNA-sequencing, Biton and colleagues identified two distinct small-intestinal Lgr5+
ISC subsets (ISC-II and ISC-III) that express components of the major histocompatibility
complex class II (MHC-II) machinery. These proliferative, relatively differentiated Lgr5+
ISC subsets can present processed antigens to naive T-helper (Th) cells and induce T-
cell activation or tolerance, consequently serving as non-conventional antigen-presenting
cells [135]. By contrast, a third more quiescent ISC-I subset displays minimal MHC-II
expression and is endowed with a more stem-like gene expression signature. Conditional
ablation of MHC-II components in intestinal epithelial cells enriched for Lgr5-expressing
cells in crypt regions and decreased CD4+ T cells in the crypt lamina propria, strongly
implicating peptide-MHC-II interactions in the regulation of the balance of cell types
in the vicinity of the crypt. Reciprocally, activated Th cells produce distinct cytokines
that influence the balance between self-renewal and differentiation of Lgr5+ ISCs [135].
In organoid co-cultures, proinflammatory signals, such as the presence of Th1, Th2, or
Th17 cells or treatment with IL13 or IL17, promoted differentiation, enriching for TA cells
with a concomitant reduction in ISCs [135]. In fact, each Th subset impacted the ISC
differentiation trajectory differently: Th1 co-cultured organoids were enriched for the
Paneth and goblet cell lineages, Th2 signals induced an enteroendocrine phenotype, Th17
cells or their cytokine IL17a reduced ISC renewal and promoted a TA cell fate, and IL13
treatment favoured tuft cell differentiation over Paneth and goblet cell types [135].
Regulatory T cells (Tregs)—a subset of CD4+ helper T lymphocytes that curtail in-
flammatory immune responses to avert the development of detrimental autoimmunity—
additionally regulate intestinal homeostasis by directly supporting ISC self-
renewal [135,136]. Accordingly, co-culture of intestinal organoids with the anti-inflammatory
Tregs, or their secreted cytokine IL10, led to expansion of the Lgr5+ ISC pool [135]. Con-
versely, mice with Treg ablation exhibited a reduction in the ISC-I subset and a shift toward
the more proliferative MHC-II+ Lgr5+ ISC-II and ISC-III subsets, consistent with depletion
of ISC-I cells through increased differentiation and coincident with the recruitment of
pro-differentiative Th (Th1, Th2, and Th17) cells to crypt regions [135].
The crosstalk between immune cells and Lgr5+ ISCs also helps shape the small-
intestinal niche post infection. Here, the balance is skewed toward the more differen-
tiated MHC-II+ Lgr5+ ISC-II and ISC-III subsets with concomitant suppression of the ISC-I
state [135]. Post bacterial infection, Th1 cytokines promote differentiation toward the
Paneth cell lineage, consistent with a requirement for the antimicrobial peptides that these
cells secrete into the niche [135,137]. On the other hand, helminth and protist infections
mobilize tuft cells to secrete IL25, leading to release of IL13 and IL4 from group 2 innate
lymphoid cells [133,138,139]. IL13, in turn, acts on epithelial crypt progenitors to evoke
differentiation of tuft and goblet cells, amplifying the so-called “weep and sweep” response
whereby increased mucus (weep) and muscle contractility (sweep) expel the helminth par-
asite from the intestinal lumen [133,139]. Interestingly, these parasites trigger a profound
remodelling and lengthening of the small intestine, underpinned by tuft cell hyperplasia,
which serves to perturb further parasite colonization—a phenomenon termed concomitant
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immunity [140]. Importantly, deletion of MHC-II in Lgr5+ ISCs compromised the tuft cell
mobilization seen in control infected counterparts and increased overall helminth load [135].
Together, these findings underscore the importance of the crosstalk between Lgr5+ ISCs
and innate and adaptive immune cells in determining the balance between stemness and
differentiation both in homeostasis and post inflammatory insult [135]. Below, we further
delineate the cellular and molecular circuitries that shape the niche post injury.
7. Niche Remodelling Post Injury
Although most studies have delineated the different crypt cell types that can mobilize
to replenish Lgr5+ ISCs post injury, the niche itself can also remodel and adapt to damage.
Thus, following Paneth cell ablation, enteroendocrine and tuft cells can be recruited to the
crypt base as a reserve source of instructive Notch signals, enabling the maintenance and
proliferation of Lgr5+ ISCs to continue unabated [122]. Another example of niche remod-
elling is observed following acute, transient Notch inhibition. Somewhat surprisingly, this
triggers rapid apoptotic demise of Notch ligand-bearing Paneth cells, leaving Lgr5+ ISCs
intact, albeit with diminished lineage-tracing capacity. Nevertheless, in this setting, both
Lgr5+ ISCs (that activate expression of Dll1) and Dll1+ multipotent progenitors can mobilize
to replenish the depleted Paneth cell pool and restore Notch homeostasis [141]. While these
results contrast with the loss of Lgr5+ ISCs and the expansion of Paneth-like cells observed
during prolonged Notch inhibition [84], they attest to the potential tolerability of transient
Notch perturbation in the clinic and underscore that different modes of injury elicit distinct
cellular and molecular responses.
Epithelial damage also leads to remodelling of the mesenchymal niche. Following
DSS-induced injury, CD34+Gp38+ non-myofibroblastic pericryptal cells express several
genes whose products promote stemness (e.g., Grem1, Rspo1), recruit neutrophils and
macrophages to the inflamed tissue (e.g., Il7, Ccl2, Csf1), and facilitate epithelial restitution
(e.g., Areg, Fgf7, Fgf10, Col1a1, Ptgs2) [91]. DSS treatment also stimulates the expression
of genes encoding various BMPs, vascular remodelling factors (e.g., ANGPT1, ANGPT2,
VEGFA), and WNT5A in CD34− lamina propria myofibroblasts, thus promoting epithelial
differentiation, repair, and regeneration of the upper villi and colonic surface epithe-
lium [91]. In the colon, which lacks a WNT-secreting epithelial cell type, Gli1+ subepithelial
mesenchymal cells serve as an essential WNT source, supporting colonic ISC renewal both
during homeostasis and following DSS-induced injury [124]. As mentioned earlier, these
cells can also mobilize as a reserve WNT source in the small intestine, if epithelial secretion
is compromised [124].
The EGF family member NRG1 has recently been identified as an important extracel-
lular cue that augments the proliferation of stem and progenitor cells in the regenerating
epithelium through downstream activation of MAPK and PI3K/AKT signalling [142].
Following DNA damage, multiple mesenchymal populations, including CSF1R-dependent
crypt-associated macrophages [130], PDGFRα+ subepithelial telocytes [105], and CD34+
PDGFRαlo trophocytes [92], as well as Paneth cells secrete NRG1 (but not EGF), driving
dedifferentiation of progenitor cells towards a more stem-like phenotype and promoting
regeneration [142].
Whereas the intestinal epithelium displays extraordinary plasticity and can regen-
erate following multiple types of injury, failure to restore barrier integrity post damage
risks translocation of intestinal microbiota, resulting in inflammation and likely predis-
posing to tumour formation. Indeed, chronic inflammation is considered a hallmark of
cancer, and inflammatory bowel disease (ulcerative colitis or Crohn’s disease) is often a
prelude to CRC [143]. Recent single-cell profiling of colonic tissues, from patients with
ulcerative colitis and healthy donors, has illuminated the contributions of the epithelial,
stromal/mesenchymal, and immune compartments to colon homeostasis and implicated
their dysfunction in inflammatory bowel disease [144–146].
Until recently, little was known about the colonic mesenchyme in humans. Aside
from pericytes and myofibroblasts, four distinct clusters of fibroblast-like cells have now
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been identified in the healthy human colon, designated stromal clusters S1–S4. Of note, the
subcryptal S2 population expresses the transcription factor SOX6, the coagulation factor
F3/CD142, the non-canonical WNT ligands WNT5A and WNT5B, the BMP agonists BMP2
and BMP5, the secreted Wnt antagonist FRZB, and the Th2 cytokine POSTN, consistent
with a pivotal role in the paracrine control of cell proliferation and differentiation in the
upper crypt [144].
The onset of colitis is associated with extensive mesenchymal niche remodelling.
Marked depletion of the mesenchymal SOX6+ S2 cell population likely underlies the
epithelial barrier disruption that typifies this condition. Conversely, a population of
activated mesenchymal S4 cells, which is barely detectable in the normal healthy colon,
expands and deploys proinflammatory and stress-response factors that recruit immune cells
to the gut mucosa. These activated S4 cells express genes such as PDPN, typically associated
with fibroblastic reticular cells (that coordinate lymphocyte migration within lymph nodes),
the potent T/B-cell chemotactic factors CCL19 and CCL21, the TNF-superfamily member
TNFSF14, the proinflammatory cytokine IL33, and lysyl oxidase (LOX) enzymes that
remodel the ECM by cross-linking collagens and elastin [144]. Accordingly, LOX/LOXL1
blockade reduced the severity of the inflammation in a DSS-induced colitis model [144].
Overall, the demise of the S2 cluster is thought to impair the regenerative capacity of
the overlying epithelium, whereas the expanded S4 cluster sustains a state of prolonged
inflammation, preventing resolution of the wound-healing response and perpetuating
tissue distress and barrier dysfunction [144].
Similarly, Smillie et al. identified a population of WNT2B+WNT5B+ inflammation-
associated fibroblasts, uniquely expanded in the inflamed as well as the cancerous colon,
and enriched for markers of colitis, fibrosis, and cancer-associated fibroblasts (CAFs) [145].
For example, one of the most highly expressed genes in this cluster, OSMR, encodes the
receptor for oncostatin M, a cytokine known to predict resistance to the anti-TNF therapy
used to treat inflammatory bowel disease [145,147]. The emergence of WNT2B+WNT5B+
inflammation-associated fibroblasts occurs alongside a marked expansion of mislocalized
M-like cells, inflammatory monocytes, and CD8+IL17+ T cells, consistent with immune
derailment/inflammation [145].
In addition to the remodelling of the mesenchymal compartment, dysfunction of
epithelial-cell subsets has also been documented in patients with ulcerative colitis. Deple-
tion of the newly identified BEST4/OTOP2 absorptive cells, implicated in pH regulation,
and the emergence of malpositioned goblet cells, displaying impaired antimicrobial func-
tion, compromise the epithelial barrier and allow bacterial invasion [146]. Collectively, the
above studies implicate aberrant remodelling of the epithelial, mesenchymal, and immune
compartments in human ulcerative colitis, underpinned by expansion and/or depletion
of newly identified rare cell types, de novo activation or repression of cell lineage-specific
gene expression modules, and rewired cell-cell interaction networks—all perpetuating a
highly dysfunctional inflammatory milieu.
8. At the Crossroads of Intestinal Regeneration and Tumorigenesis—The YAP-Driven
Foetal-Like Signature
Additional studies have interrogated the molecular mechanisms underlying the re-
sponse of the mouse intestinal epithelium to helminth infection [148] and DSS-induced
injury [149], both of which breach the mucosal barrier. An emergent theme is that the regen-
erating intestinal epithelium is transiently reprogrammed into a highly plastic foetal-like
state, orchestrated by changes in the inflammatory milieu [148] and ECM [149], respectively.
The extensive tissue remodelling that ensues entails the deployment of highly proliferative
SCA1+ progenitors [148,149], lacking markers of secretory lineages as well as of adult
ISCs—most notably, Lgr5 and LRIG1 [39,149]. Instead, these regenerating cells express
foetal epithelial markers, such as Anxa1 and Tacstd2/Trop2, alongside the multipotent
progenitor marker SCA1 (also known as LY6A) [149,150]. Notably, although Sca1 is absent
from the human genome, ANXA1 is highly expressed in the regenerating epithelium of
inflamed ulcerative colitis, compared with non-inflamed regions in matched patient speci-
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mens [149]. Moreover, the transcriptional signatures of the mouse repairing epithelium
and the foetal-like state are enriched in patients with active inflammation, compared with
healthy counterparts, lending relevance of this foetal-like program to human disease [149].
Similarly, crypts overlying helminth larvae-associated granulomas become devoid of Lgr5
expression, with a discrete subset of SCA1+ crypt cells activating an IFNγ-dependent
foetal-like transcriptional program [148]. Indeed, similar injury-response programs are
deployed following irradiation and DTR-targeted Lgr5+ ISC ablation, suggesting that
the transient “revival” of latent foetal-like traits is likely a common denominator of the
intestinal epithelial response regardless of the mode of injury [148].
Following DSS treatment, the regenerating mouse intestinal epithelium is also charac-
terized by upregulation of several ECM components and the accumulation of collagen type
I fibres around newly formed crypts. These dynamic changes in the ECM composition of
the niche are propagated via FAK/SRC-mediated mechanotransduction, culminating in the
activation and nuclear translocation of YAP and TAZ [149], two paralogous transcriptional
coactivators inhibited by the Hippo tumour-suppressor pathway [151]. YAP has similarly
been shown to transiently reprogram Lgr5+ ISCs into a regenerative state post irradiation.
Here, YAP suppresses homeostatic Wnt signalling and Paneth cell differentiation while
concomitantly activating expression of the EGF-family member EREG to drive proliferation
and promote cell survival [152]. Indeed, several studies concur that YAP/TAZ can inhibit
Wnt signalling during intestinal regeneration and tumorigenesis [152–155], consistent
with the suppression of Lgr5 and the ISC signature during the foetal-like regenerative
response [149].
A critical role for YAP has also been ascribed in the damage-induced mobilization of
“revival stem cells”, recently identified in the regenerating intestinal epithelium using a
single-cell transcriptomics approach [156]. The revival stem cell pool is a rare, quiescent
population in homeostasis, characterized by elevated expression of clusterin (Clu), Anxa1,
Cxadr, and Basp1. While these Clu+ revival stem cells do not contribute to daily homeostatic
renewal, they are mobilized and expanded following DTR-mediated ablation of Lgr5+
ISCs, irradiation, or DSS-induced inflammation and colitis. Their transient expansion
post damage regenerates the full gamut of intestinal cell types, including Lgr5+ ISCs, in a
YAP1-dependent manner [156]. Interestingly, Clu+ revival stem cells express elevated levels
of Sca1 post irradiation [156], raising the possibility that this damage-induced, expanded
revival stem cell population overlaps with Sca1+ foetal-like crypt cells, which also rely on
YAP for their regenerative potential [149].
The lipid transporter TIPE0 (also known as TNFAIP8) has recently been recognized as
an important regulator of the Clu+ regenerative program, with Tipe0−/− mice exhibiting
poor recovery from DSS-induced injury and reduced subsequent survival [157]. Underlying
this phenotype is a broad dysfunction of plasticity programs, characterized by an over-
abundance of Lgr5+ ISCs and partially differentiated cells in homeostasis, and an impaired
capacity to dedifferentiate post injury. Indeed, although Tipe0−/− enterocytes are induced
to proliferate post injury, they fail to recruit YAP to the nucleus and are hence impeded
from mounting a Sca1+Clu+ regenerative response, leading to intestinal demise [157].
Whereas the YAP-driven regenerative response is a transient, reversible
process [149,156], persistent tissue injury and repair set up a vicious cycle of chronic
inflammation—a known risk factor for CRC [143] as discussed previously. Indeed, the
YAP-mediated regenerative response can be hijacked to facilitate the progression of APC-
deficient foci to adenomas to the extent that Yap deletion abrogates adenoma forma-
tion in ApcMin/+ mice [152,158]. Moreover, the YAP transcriptional program correlates
with the gene expression signatures of early ApcMin/+ tumours as well as of revival stem
cells [156,159]. Accordingly, YAP decorates the nuclei of tubular adenomas from patients
afflicted with familial adenomatous polyposis [158]. Yet, the role of YAP in intestinal
tumorigenesis remains controversial as both tumour-suppressive [153,155] and oncogenic
functions [152,158,160,161] have been ascribed in different contexts. It further remains to be
seen whether the foetal-like, YAP/TAZ-dependent, Lgr5− regenerative state plays a role in
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the development of colonic tumours lacking overt Wnt-pathway mutations. In support of
this notion, BRAFV600E-driven colonic organoids exhibit a foetal-like dedifferentiation pro-
gram enriched for Hippo-pathway targets, which recapitulates the transcriptional profiles
of human BRAFV600E-driven CRCs [162], although in vivo validation is currently lacking.
From a therapeutic standpoint, the acquisition of a YAP/TAZ-dependent foetal-like
signature reportedly underpins resistance to Wnt-targeted therapy. To recapitulate the
CRC mutational landscape, Han and colleagues [163] generated mouse colonic organoids
harbouring oncogenic Ptprk-Rspo3 fusions, KrasG12D or BrafV600E, and loss-of-function
mutations in the tumour-suppressor genes p53 and Smad4. Transient exposure of these
organoids to TGFβ, intended to select for Smad4-mutant lines, conferred resistance to
PORCN inhibition, signifying that the emergent organoids had lost their dependence on
Wnt signalling. Similarly to the regenerating epithelium, this WNT-independent growth is
associated with YAP/TAZ-dependent transcriptional reprogramming and reversion to a
foetal-like state, which crucially retains sensitivity to YAP/TAZ inhibition [163].
A newly discovered upstream regulator of YAP signalling suggests another potential
therapeutic vulnerability. PGE2—secreted into the niche by a rare population of PTGS2-
expressing pericryptal fibroblasts—drives the expansion of Sca1+ reserve-like stem cells,
with a regenerative/tumorigenic YAP transcriptional signature and concomitant suppres-
sion of β-catenin signalling, fuelling adenoma initiation in ApcMin/+ mice as well as an
azoxymethane-induced tumour model. Crucially, the tumorigenic capacity of these Sca1+
reserve-like stem cells depends on the druggable PGE2–PTGER4 axis, which in turn con-
trols the nuclear localization/activity of YAP [159]. Indeed, PGE2-induced YAP signalling
is also implicated in colitis-associated regeneration and spontaneous tumorigenesis [164].
These results exemplify the contribution of a proinflammatory mesenchymal niche to
tumour initiation. Perhaps more importantly, they suggest a therapeutically actionable
target for the pro-oncogenic, YAP-dependent, foetal-like regenerative program.
Overall, multiple cell types can mobilize to regenerate the injured intestinal epithelium
by adopting a highly plastic foetal-like state, although the degree to which each popu-
lation contributes to the repair warrants further study. It also remains unclear whether
regenerative cues can mobilize different crypt progenitors and/or mature cell types to
dedifferentiate into a foetal-like state, and/or whether pre-existing homeostatic crypt cell
types, such as the Lgr5−Clu+Sca1+ revival stem cells [156], expand in an attempt to restore
the epithelium independently of Wnt signalling. Furthermore, whether revival stem cells
can serve as tumour-initiating cells remains untested at present. For example, it is con-
ceivable that PGE2-dependent Sca1+ reserve-like tumour-initiating cells [159] derive from
transformation of Lgr5−Clu+Sca1+ revival stem cells [156]. Consistent with this notion,
the revival stem cell signature correlates with resistance to 5-fluorouracil chemotherapy
in patient-derived CRC organoids, and elevated CLU expression is associated with poor
patient survival and disease recurrence [165]. In addition, the revival stem cell signature is
reportedly enriched in L1CAM-positive metastasis-initiating CRC cells [166], a point we
return to later.
9. Nutritional Cues and ISC Function
Several studies have contended that organismal nutritional status, quality of nutrient
intake, and different dietary regimens modulate ISC behaviour and regenerative capacity
as well as impact the composition and diversity of the gut microbiota. As the roles of
dietary factors and host–microbiota crosstalk in intestinal homeostasis and disease have
been extensively reviewed [167–173], herein we highlight key findings that inform on how
nutrients and microbiota contribute to the niche in homeostasis, and how they erode ISC
function in tumour progression.
A high-fat diet and obesity promote proliferation of Lgr5+ and Lgr5− ISCs, including
progenitor populations, in a PPARδ-dependent manner likely expanding the ISC pool
vulnerable to transformation [174]. In this instance, ISCs exhibit β-catenin-dependent up-
regulation of the Notch ligands JAG1 and JAG2. This cell-autonomous activation of Notch
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signalling renders ISCs independent of the Paneth cell niche, the source of Notch ligands
in non-pathological conditions. Gaining independence from niche signals predisposes
to deregulated ISC self-renewal and tumorigenesis, with the corollary that fasting and
dietary intervention may influence ISC behaviour, CRC risk, and treatment efficacy. Of
note, excess dietary cholesterol also stimulates ISC proliferation and promotes tumour
formation in ApcMin/+ mice, but does so directly by impacting phospholipid remodelling
and the membrane lipid composition of Lgr5+ ISCs [175].
A high-fat ketogenic diet promotes Lgr5+ ISC stemness and regenerative capacity
post injury through the activation of Notch signalling [176]. Expression of HMGCS2—the
rate-limiting enzyme in the biosynthesis of ketone bodies produced by the breakdown
of fat—is highly enriched in Lgr5+ ISCs relative to differentiated cells. Its product, β-
hydroxybutyrate (βOHB), inhibits class 1 histone deacetylase (HDAC) enzymes, leading
to the activation of Notch target-gene expression. Accordingly, Hmgcs2 deletion depleted
βOHB levels in Lgr5+ ISCs, impaired Notch-driven self-renewal potential, and prompted
their differentiation towards a secretory cell fate, outcomes which could be prevented
by exogenous βOHB or HDAC inhibitors. Importantly, a glucose-supplemented diet
phenocopied the effects of Hmgcs2 deletion: it suppressed Hmgcs2 expression in Lgr5+ ISCs,
reduced crypt βOHB levels, dampened Notch signalling, and diminished lineage tracing
from Lgr5+ ISCs post irradiation [176]. A ketogenic, low carbohydrate diet, therefore,
promotes Notch-pathway activity and sustains a mobilizable pool of Lgr5+ ISCs that can
readily replenish the epithelial lining post injury, whereas a high-sugar diet suppresses
ketogenesis and compromises Lgr5+ ISC regenerative capacity [176].
Recent studies have directly implicated the Western diet—high in fat and low in
calcium and vitamin D—in the differential mobilization of distinct ISC pools during
homeostasis and tumorigenesis [177]. Wild-type mice fed a Western-style diet (NWD1),
formulated with nutrients known to increase the risk of CRC (higher fat; lower vitamin D3,
calcium, folate/methionine, and fibre) [178,179], develop both large- and small-intestinal
tumours, which recapitulate the incidence and latency of human sporadic CRC [180]. Sur-
prisingly, lineage tracing of emergent tumours in this model showed that they harbour a
reduced number of Lgr5+ cells but an increased proportion of Bmi1+ cells [181]. During
tumour latency, NWD1-fed mice appear normal but nevertheless harbour multiple changes
in their histologically normal mucosa, including an enlarged proliferative zone, perturbed
cell differentiation patterns, and expanded Wnt signalling throughout the mucosa of their
small-intestinal villi and colonic crypts, pointing to a dysfunctional stem cell compart-
ment [180,182]. Indeed, both the repopulating ability and tumour-initiating potential of
Lgr5+ ISCs from NWD1-fed mice were severely impaired [183]. Replenishing higher lev-
els of dietary vitamin D3 restored Lgr5+ ISC stemness [183]. Deletion of the Vdr gene,
encoding the vitamin D receptor, recapitulated the effects of the NWD1 diet, with Lgr5+
cells unable to repopulate the crypt during homeostasis [183] and Bmi1+ ISCs mobilized
in their stead [177]. These studies establish vitamin D as a key ingredient of the nutrient
niche, linking Lgr5+ ISC stemness with physiological gut function. They also suggest
further important avenues for research into how and which dietary factors influence the
mobilization of different stem cell populations in distinct modes of injury, tumour subtypes,
as well as post therapy, which may also inform potential dietary intervention strategies.
The above studies further raise a cautionary note about the differences in nutrient
levels between mouse chows and the human diet. For example, mouse chows typically
supply higher vitamin D levels than consumed by humans [177,181,183] whereas, in fact, an
increased risk of CRC is associated with vitamin D deficiency [184]. Moreover, the reliance
of the stem cell function of Lgr5+ ISCs on vitamin D receptor signalling, coupled with the
fact that Lgr5+ ISCs enter quiescence in its absence, raises the provocative possibility that
Lgr5+ ISCs may not be as readily mobilizable under diets recapitulating low vitamin D
intake that are more relevant to the human condition [183]. It is also noteworthy that the
levels of fat (60%), typically administered in so-called high-fat diets [174], are considerably
higher than those found in the diets of obese humans, and they confer a markedly more
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pronounced metabolic response relative to a 45% fat diet, which better recapitulates human
physiology [185,186]. These considerations have led some scientists to question whether
such high-fat diets provide an appropriate model for human diet-induced obesity [185,186].
In addition, different diets have been shown to profoundly alter the gene expression
landscapes of Lgr5+ ISCs, underscoring the importance of considering the composition of
the diet in the experimental design and prompting the recommendation for transparent
reporting of dietary context in stem cell studies [187].
Aside from the quality of nutrition, fasting and caloric restriction regimens have
enjoyed recent attention on account of their purported benefits in extending lifespan and
counteracting age-associated attrition of gut and ISC function [188]. Prolonged calorie
restriction elicits a reduction in small-intestinal epithelial mass and stimulates Paneth cell-
derived paracrine signalling, priming the niche for rapid Lgr5+ ISC expansion following
nutrient repletion [189]. In contrast, acute nutrient deprivation mobilizes mTert+ ISCs to
repopulate the epithelium upon re-feeding [190], suggesting differential mobilization of
ISC pools following distinct types of dietary perturbation. From a therapeutic standpoint,
fasting protects Lgr5+, Bmi1+, and HopX+ ISC populations from DNA damage [191] and
alleviates chemotherapy-induced toxicity in both mice and patients [191]. Mechanistically,
fasting induces a PPARδ-dependent fatty acid oxidation program in ISCs and progenitor
cells, which channels triglycerides and free fatty acids into acetyl-CoA/energy production,
improving regenerative potential and counteracting the age-associated decline in intestinal
function [192].
Given that fasting and a high-fat diet differ drastically with respect to calorie intake,
it is surprising that a high-fat diet also activates PPARδ signalling and augments the
self-renewal capacity of both Lgr5+ and Lgr5− ISCs [174]. Furthermore, ectopic PPARδ
signalling increases the tumour-initiating efficiency of intestinal progenitors following
loss of Apc [174,193]. In this regard, it is worth considering that prolonged consumption
of a high-fat diet exposes ISCs to an excess of dietary fatty acids over the longer term,
persistently deregulating β-catenin transcriptional activity and expanding both Lgr5+ and
Lgr5− ISCs independently of niche constraints [174]. By contrast, acute fasting mobilizes
scant reserves of free fatty acids from adipose stores to restore diminishing ISC function as
part of a transient adaptive response to nutrient deprivation [174,192]. Notwithstanding
these differences, PPARδ is emerging as a key, druggable metabolic node that controls ISC
fate and function in response to nutritional cues, such as changes in nutrient availability and
quality. Interestingly, PPARδ was recently implicated in mediating the effects of a high-fat
diet on colonic tumour initiation and liver metastasis via the activation of its downstream
target, the pluripotency factor NANOG [194], underscoring its pleiotropic modes of action
in regulating stemness and tumour progression. Whether aberrant activation of fatty acid
oxidation per se contributes to tumorigenesis awaits further investigation [192], although
recent studies have linked activation of this pathway to anoikis resistance in metastasizing
CRC cells [195]. Together, these findings hold promise for the use of fasting regimens and
PPARδ agonists in ameliorating intestinal dysfunction and improving the tolerability and
efficacy of current chemotherapies [191,192] but, conversely, advocate the evaluation of
PPARδ antagonists in the CRC setting—particularly for obese patients. Interrogating which
pathways downstream of PPARδ are activated in distinct settings/CRC subtypes, and
distinguishing which PPARδ coactivator/corepressor interacting partners are recruited to
its homeostatic roles in normal ISC physiology, and which can impact oncogenesis, may
yield valuable therapeutic insights.
10. Microbiota-Derived Metabolites and ISC Function
The gut microbiota—a complex ecosystem of bacteria, archaea, eukaryotes, and viruses
that inhabit the intestinal tract—benefit from host nutrient intake and, in turn, influence
host metabolism, physiology, nutrition, and immune function. The gut microbiota ferment
indigestible by-products of host digestion, such as dietary fibre, and metabolize ingested
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nutrients, xenobiotics, and bile acids to produce energy, short-chain fatty acids, lactate,
various vitamins, and other nutritious metabolites [168–173].
Ingested dietary nutrients can, therefore, drastically alter the microbiota landscape
and metabolic output. In turn, microbiota-derived metabolites can directly impact ISC
function and gut homeostasis in multiple ways [168–173]. For example, dietary fibre is
fermented by commensal bacteria in the colon, generating short-chain fatty acids such
as butyrate, a pleiotropic metabolite which functions both as an energy source and an
HDAC inhibitor. Of note, butyrate also helps regulate immune homeostasis in the gut.
It promotes immune tolerance by downregulating the expression of proinflammatory
mediators [196,197], desensitizing lamina propria macrophages to commensal micro-
biota [196,197], and inducing Treg differentiation [198,199].
Functioning as an HDAC inhibitor, butyrate can suppress the proliferation of ISCs
in vitro by enhancing the promoter-binding activity of the cytostatic transcription factor
FOXO3 [200]. In vivo, however, bacterial-derived butyrate can only inhibit ISC proliferative
capacity following disruption of the crypts by injury as it is normally excluded from
the niche. Indeed, during homeostasis, the elaborate crypt configuration ensures that
differentiated colonocytes metabolize butyrate, forming a metabolic barrier that restricts
the levels of butyrate “trickling down” to the crypt base, thereby shielding vulnerable
ISCs from its cytostatic effects [200]. The ability of butyrate to inhibit ISC proliferation
comes into play, however, following colonic mucosal injury. By inhibiting ISC proliferation,
butyrate delays the regenerative response until the wound is sealed, reducing the risk of
exposing proliferating Lgr5+ ISCs to bacterial genotoxins, which could cause DNA damage
and elicit their transformation [200].
Notably, butyrate exerts differential effects on proliferation and apoptosis in normal
versus cancerous colonocytes, a conundrum known as the “butyrate paradox” [201,202].
Whereas normal, differentiated colonocytes metabolize butyrate as an energy source to
sustain proliferation [203], cancerous colonocytes opt for aerobic glycolysis, on account
of the Warburg effect, leading to the accumulation of butyrate [204]. In this context, the
excess butyrate functions as an HDAC inhibitor, causing hyperacetylation of core histones
and leading to the expression of genes whose products inhibit cell proliferation and induce
apoptosis [201,204]. Although widely regarded, therefore, as a tumour-suppressive metabo-
lite [196,202], butyrate has also been shown to exert pro-tumorigenic effects further adding
to its namesake paradox. Belcheva et al. found that butyrate fuels colonocyte proliferation
and promotes polyp formation in an ApcMin/+Msh2−/− mouse model, potentially linking
butyrate-producing commensal bacteria to the pathogenesis of CRC [205]. Differences in
the host genetic background and age, gut microbiota status, chow formulation/dietary fibre
source, tumour subsite location within the colon, and the local metabolite milieu (e.g., the
presence of interacting metabolites) may all contribute to this apparent paradox [206,207].
Nevertheless, this context-dependence lends hope for the development of antibiotic and
dietary interventions that could harness the microbiome to influence disease progression
and improve therapeutic outcome.
Secondary bile acids are another important class of metabolites that are produced
by the gut microbiota from unabsorbed primary bile acids. They facilitate absorption of
dietary fats and fat-soluble vitamins while also serving as pleiotropic signalling molecules
through the activation of both their cognate nuclear receptor, FXR [208], and the G protein-
coupled bile acid receptor, TGR5 [209]. Elevated faecal levels of secondary bile acids,
particularly deoxycholic acid and lithocholic acid, are associated with the consumption of a
high-fat/high-protein and low complex carbohydrate diet, and correlate with an increased
predisposition to CRC [210,211]. Directly linking high-fat diet-induced accumulation of
bile acids to tumour initiation, excess colonic bile acids have been shown to erode the
crypt–villus architecture in mice, perturbing locoregional Wnt-signalling gradients and
exposing Lgr5+ ISCs to luminal genotoxins and ensuing transformation [208]. Feeding
ApcMin/+ mice a high-fat diet shifted bile acid metabolism toward the increased production
of tauro-β-muricholic acid and deoxycholic acid, which antagonize the function of the bile
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acid receptor FXR, stimulating Lgr5+ ISC proliferation, causing DNA damage and genomic
instability, and facilitating adenocarcinoma progression. Notably, these effects could be
curtailed by FXR agonists, which are currently under clinical evaluation [208].
Bile acids also relay nutrient availability by activating the receptor TGR5 in Lgr5+
ISCs, thus coordinating daily intestinal epithelial turnover post food intake. Release
of bile acids into the intestinal lumen is sufficient to stimulate Lgr5+ ISC self-renewal,
TA progenitor proliferation, and specification into the goblet and enteroendocrine cell
lineages via TGR5 [209]. Loss of TGR5 function in Lgr5+ ISCs exacerbated DSS-induced
damage and impaired the regenerative capacity of the colonic epithelium, implicating
bile acid–TGR5 signalling in regeneration post injury [209]. Mechanistically, the bile acid–
TGR5 axis promotes intestinal regeneration via SRC/YAP signalling and engagement
of the foetal regenerative program [149,209]. Together, these findings cast bile acids as
potent, pleiotropic oncometabolites that can influence both Lgr5+ and Lgr5− populations,
expanding the potential tumour-initiating pool.
Microbiota-derived lactate has also been shown to promote Lgr5+ ISC proliferation,
albeit indirectly, by enhancing Wnt/β-catenin signalling in Paneth cells and αSMA+ intesti-
nal stromal cells via the GPR81 receptor [212]. Typically, the highly glycolytic Paneth cells
in the small intestine supply neighbouring Lgr5+ ISCs with lactate, used to fuel oxidative
phosphorylation and sustain their prolific mitochondrial metabolism [115]. Rather than
altering metabolic output, however, it seems that commensal microbiota-derived lactate
may serve to reinforce the nurturing functions of Paneth and stromal cells, particularly by
stimulating the increased secretion of WNT3, to support the regenerative capacity of Lgr5+
ISCs [212]. Interestingly, oral administration of lactate or probiotics protects mice from
radiation- and chemotherapy-induced intestinal damage, which argues in favour of their
prophylactic administration to ameliorate gut injury sustained in response to genotoxic
therapy [212].
Although not a microbiota-derived metabolite per se, arachidonic acid deserves
mention as an essential dietary fatty acid with broad anti-microbial properties that may
influence both the microbiota landscape [213] and ISC function [214]. As such, arachidonic
acid is thought to selectively favour the growth of commensal bacteria but suppress the
proliferation of pathogenic microbiota [213], in addition to enhancing the proliferative
and regenerative response of the small-intestinal epithelium to irradiation [214]. Mecha-
nistically, arachidonic acid elevates the expression of Ascl2, the master regulator of Wnt
signalling [73,214]. Yet, interestingly, arachidonic acid exerts its pro-regenerative effects
on the recently described Msi1+ radioresistant ISC pool [45,214], rather than Lgr5+ ISCs,
which are in fact depleted by arachidonic acid treatment [214].
Overall, the above findings establish dietary nutrients and microbiota-derived metabo-
lites as important influencers of stemness with the capacity to mobilize both Lgr5+ and
Lgr5− populations, confer independence from the niche, and expand the cell pool vul-
nerable to transformation. An improved understanding of how ingested nutrients and
microbiota-derived metabolites influence the function of the various ISC subpopulations
may inform the development of effective dietary or pharmacologic intervention strategies
to mitigate CRC risk. Additionally, new insights may lead to the development of probiotics
and dietary supplements as potential adjunct regimens for improving the tolerability and
efficacy of CRC therapies.
11. Microbiota Contributions to the Niche
The evidence discussed above converges on the pivotal roles of the intestinal micro-
biota and their metabolites in influencing ISC function during homeostasis, post-injury
regeneration, and CRC progression. The intestinal microbiota can impact each of these
processes in multiple different ways. These include curtailing or promoting inflamma-
tion, impairing or reinforcing gut-barrier integrity, perturbing invasive bacterial species
from colonizing the gut, influencing the host immune response, generating genotoxins
that damage the host DNA, modulating the balance between ISC self-renewal and dif-
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ferentiation, and altering the metabolic milieu (reviewed in [167–171,173]). Moreover,
dysbiosis—an imbalance of the commensal and pathogenic microbial communities in the
gut—has been increasingly recognized as a prelude to colonic inflammation [215] and a
catalyst of inflammation-associated CRC initiation and progression [167,216–219].
The microbiota composition and abundance differ significantly along contiguous
intestinal segments, with the large intestine/colon typically displaying a higher bacterial
burden and species diversity compared with the small intestine [220]. In addition, distinct
taxa colonize diverse regions along the tissue–lumen axis as influenced by locoregional nu-
trient availability, oxygen gradients, pH conditions, and metabolic specialization [220,221].
As a result, microbiota-derived metabolites also vary regionally creating multiple local
metabolite milieux that can profoundly impact gut physiology and tumorigenesis [220,221].
Although the majority of gut microbiota reside either in the lumen or within the mucus
layer above the villi, a select contingent of aerobic, non-fermentative genera (Acinetobacter,
Stenotrophomonas, and Delftia) inhabit murine ceacal and proximal colonic crypts [222].
These so-called “crypt-specific core microbiota” augment the homeostatic function of
closely apposed Lgr5+ ISCs [223]. Recently, an analogous community of crypt-specific core
microbiota has been reported to colonize human colonic crypts and to become dysbiotic in
CRC [224].
The presence of microbial components can directly impact the proliferation and differ-
entiation of ISCs and affect their role in preserving the integrity of the epithelial barrier.
Lgr5+ ISCs are equipped with both cell-surface (TLR4) and intracellular (NOD2) pattern
recognition receptors that enable the detection of shed bacterial components. In the small
intestine, engagement of TLR4 by its bacterial cell wall-derived ligand, lipopolysaccharide,
inhibited the proliferation of Lgr5+ ISCs and induced PUMA-dependent apoptosis, sug-
gesting that invading pathogens may directly target Lgr5+ ISCs and perturb their ability
to regenerate the epithelium post infection [225]. Having identified that colonic crypts
harbour the so-called crypt-specific core microbiota [222], Naito and colleagues assessed
how their presence impacts colonic ISC function in homeostasis [223]. Monocolonization
of germ-free mice with individual members of the crypt-specific core microbiota [222]
activated TLR4 signalling, leading to a shift toward goblet cell differentiation and eliciting
proinflammatory necroptosis of ISCs and TA cells [223], in contrast to the small intestine
where immunosuppressive apoptosis was the predominant mode of cell death [225]. TLR4-
induced necroptosis of ISCs may therefore help maintain crypt homeostasis by regulating
the balance between cell proliferation and differentiation in the colonic epithelium, but it
may also serve to initiate an antimicrobial inflammatory response to translocated micro-
biota [223]. Notably, excessive TLR4 signalling delays mucosal healing and precipitates a
pronounced inflammatory storm as seen when the immature immune system encounters
bacterial translocation in necrotizing enterocolitis, a leading cause of death in premature
infants [225].
Lgr5+ ISCs also express the intracellular innate immune NOD2 receptor, which can
detect the muramyl dipeptide (MDP) motif of peptidoglycan, another component of the
bacterial cell wall [226]. Following irradiation, binding of MDP to NOD2 recruits the
autophagy effector ATG16L1, which instigates the removal of damaged mitochondria
and harmful reactive oxygen species by mitophagy. Consequently, MDP-induced NOD2
signalling enhances ISC survival and preserves regenerative capacity without evoking a
detrimental inflammatory response [226,227]. Interestingly, another study showed that
Bmi1+ +4/reserve ISCs were depleted in irradiated Nod2−/− mice, suggesting that NOD2
not only protects Lgr5+ ISCs from damage but also safeguards Bmi1+ +4/reserve cells [228].
Failure to engage MDP–NOD2 signalling could therefore severely compromise the re-
generative ability of the intestinal epithelium and perpetuate inflammatory damage, as
exemplified in Crohn’s disease, frequently associated with NOD2 mutations or polymor-
phisms [227]. Thus, microbe-associated molecular patterns impact the function of ISCs in
profoundly different ways. How ISCs distinguish between commensal and pathogenic
bacteria, however, remains unclear.
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Commensal microbes can also help restore ISC function following inflammatory as-
sault. For example, the probiotic strain Lactobacillus reuteri D8 augments the proliferation of
Lgr5+ ISCs and Paneth cells, ameliorating the damage caused by TNFα in small-intestinal
organoids and by DSS in mice [229]. Sensing of the L. reuteri metabolite indole-3-aldehyde,
by the AhR receptor on co-cultured human lamina propria lymphocytes, stimulated secre-
tion of IL22, driving pro-proliferative STAT3 signalling in Lgr5+ ISCs and Paneth cells [229].
L. reuteri also stimulated the proliferation of Lgr5+ ISCs by elevating RSPO expression
and activating Wnt/β-catenin signalling [230]. In the setting of TNFα-induced inflamma-
tion, the presence of L. reuteri ensured that the number of Lgr5+ ISCs was maintained,
concomitant with the induction of Paneth cell differentiation, leading to the release of an-
timicrobials that restricted colonization by the attaching and effacing pathogen Citrobacter
rodentium [230]. These findings exemplify how commensal bacteria and their metabolites
can impact ISC homeostasis and reinforce the epithelial barrier against inflammatory insult
and pathogen infection. Future studies will no doubt shed light on the key gut microbiota–
host interactions and immune cell circuits, involved in regulating the maintenance and
activity of different ISC populations in homeostasis and disease, and address whether these
can be harnessed for therapeutic benefit.
Few studies to date have examined how pathogenic bacterial invasion impacts ISCs
and their niche. A recent study showed that the enteric pathogen Clostridioides difficile
deploys the exotoxin TcdB to disrupt epithelial polarity and crypt architecture by targeting
β-catenin/E-cadherin complexes and the scaffold protein Ezrin. Indeed, C. difficile causes
damage deep into the epithelium, exposing the Lgr5+ ISCs that are ordinarily protected at
the crypt base. Pathogenic infection of Lgr5+ ISCs attenuates Wnt signalling and impairs
their ability to regenerate the injured epithelium, exacerbating tissue damage, delaying
recovery, and predisposing to re-infection [231]. In a Salmonella enterica colitis model, the
pleiotropic bacterial effector AvrA dampens proapoptotic innate immune responses and
suppresses inflammation [232] while paradoxically activating Wnt/β-catenin signalling to
increase the number of ISCs and proliferating cells [233]—all part of an elaborate strategy to
evade host immune defences and maintain the ISC niche so as to ensure long-term survival
of the pathogen within the host [233]. Such chronic Salmonella infections can increase the
risk of CRC. Relative to AvrA− counterparts, AvrA+ Salmonella typhimirium significantly
increased tumour incidence in an inflammation-associated azoxymethane/DSS colon
cancer model, intriguingly shifting the tumour topography from the distal (left) to the
proximal (right) colon [234]. Emergent tumours in this model display activation of β-
catenin signalling and elevated expression of the BMI1 stem cell marker, consistent with
the notion that the AvrA effector subverts host ISC-signalling pathways [234].
As mentioned above, CRC progression is often accompanied by pronounced changes
in the abundance, composition, and diversity of microbiota both in the tumour and the
adjacent mucosa, termed dysbiosis [167,216–218]. In fact, changes in the microbiota and
their associated metabolome are detectable from the very early stages of CRC, implicating
such dysbiotic changes in disease aetiology [235]. Interestingly, distinct microbiota profiles
associate preferentially with each CRC subtype [236,237], and the composition of the micro-
biota differs significantly between right- and left-sided colon tumours [219,224,238], likely
reflecting the profound differences in the underlying disease pathology. For example, one
study found that Fusobacterium periodonticum and Bacteroides fragilis were more prevalent in
right-sided tumours, whereas Parvimonas micra dominated left-sided lesions [224]. Indeed,
right-sided CRCs emerge proximal (right) to the splenic flexure in a very different milieu,
compared with left-sided CRCs (distal), and are thought to progress through an alternative
serrated neoplasia pathway, molecularly underpinned by mutations in BRAF or KRAS,
microsatellite instability, and a CpG island methylator phenotype [239,240]. Of note, pa-
tients with right-sided/proximal colon cancer typically harbour invasive multi-microbial
communities encased in a complex protective ECM—termed biofilms—both in their tu-
mour mucosa and the tumour-distant normal mucosa [238], implicating such biofilms
and the inflammation they incite in the pathogenesis of right-sided disease [167,238]. The
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presence of biofilms on the normal mucosa of sporadic CRC patients is believed to indicate
a tissue primed for tumorigenesis [238]. Similar colonic biofilms, enriched for Escherichia
coli and B. fragilis, have also been detected in patients with familial adenomatous polypo-
sis [241].
The depletion of gut microbiota through antibiotic treatment markedly attenuates
tumour burden in multiple models, and germ-free animals are resistant to intestinal tumori-
genesis [205,242–246], reinforcing the notion that the development of CRC is influenced
by microbiota–host crosstalk. Several bacterial species have been implicated in promoting
tumorigenesis in humans such as Fusobacterium nucleatum [247–249], E. coli that produce
the genotoxin colibactin [241,245], and enterotoxigenic B. fragilis [241,250]. For example,
the abundance of F. nucleatum increases along the adenoma-carcinoma sequence [247,248],
and its enrichment correlates with poor patient survival [249]. Mechanistically, F. nucleatum
deploys the FadA adhesin, a virulence factor which binds E-cadherin thereby facilitating
host-cell bacterial invasion, activation of Wnt/β-catenin signalling, and the induction
of proinflammatory genes [251]. Remarkably, F. nucleatum, and its associated Bacteroides,
Selenomonas, and Prevotella species, have been detected in distal metastatic lesions as well as
in their respective primary tumours, with the corollary that F. nucleatum and its associated
microbiota may form a “mobile niche”, which disseminates aboard circulating tumour cells
to the distant site while abetting metastatic competence [246]. Colorectal tumours with a
high F. nucleatum load are also more likely to recur post chemotherapy, with the bacteria
able to exploit TLR4 and MYD88 innate immune signalling to induce autophagic survival
and resistance to chemotherapy [252]. Encouragingly, treatment of xenograft-bearing
mice with the antibiotic metronidazole reduced the F. nucleatum burden and compromised
cell proliferation and tumour growth, advocating for the development of antimicrobial
therapeutic interventions for F. nucleatum-associated CRC [246].
Several recent studies have further underscored the links between dysbiosis and
CRC. Mice lacking the cytoplasmic, innate immune, double-stranded DNA sensor AIM2
show aberrant Wnt signalling and an expansion of Prox1+ ISCs, predisposing to colonic
tumour development following treatment with azoxymethane and DSS [253]. Aim2−/−
mice harbour dysbiotic microbiota comprising multiple CRC-associated species and, strik-
ingly, their tumour burden was considerably decreased upon exposure to gut microbiota
from co-housed wild-type mice. Conversely, the colonic tumour burden of the co-housed
wild-type mice was increased, compared with individually housed wild-type counterparts,
implicating dysregulation of transmissible microbiota as an underlying cause [253]. These
findings implicate AIM2 in the protection against inflammation-associated tumorigenesis
through its ability to modulate the gut microbiota and suggest that microbiota engraftment
may help limit tumour development in CRC patients with loss-of-function mutations in
AIM2 [253].
A further landmark study recently established a driver role for colibactin-producing
bacteria in CRC tumorigenesis. Whole-genome sequencing of organoids, repeatedly ex-
posed to colibactin-producing pks+ E. coli, revealed that emergent cells harboured two
distinctive mutational signatures characteristic of human CRC, strongly implicating pks+ E.
coli and colibactin-induced genotoxic damage in CRC development and progression [254].
In another intriguing recent study, Kadosh et al. reported that the regional gut microbiota
and, in particular, high levels of the bacterial-derived metabolite gallic acid altered the
phenotype of mutant p53 from a tumour suppressor to an oncogene in two models of
Wnt-driven colon cancer [255]. The functionality of mutant p53 varied depending on the
location of the cells along the length of the intestine, indicating that p53 oncogenic and
tumour-suppressive functions may be more pliable than generally thought. In the prox-
imal gut of CKIa∆gut and ApcMin/+ mice, mutant p53 (p53R172H or p53R270H) surprisingly
suppressed the development of dysplasia and tumorigenesis, respectively, by counteract-
ing Wnt-driven hyperproliferation. In the distal gut, however, mutant p53 switched to
an oncogenic mode of action whereby it hyper-activated Wnt signalling and enhanced
tumorigenesis [255]. Eradication of the gut microbiota, by treatment with antibiotics, re-
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duced Wnt activity, decreased cell proliferation, and prevented the onset of dysplasia in the
ileum and colon of CKIa∆gutp53R172H mice, suggesting that the regional microbiota likely
counter the tumour-suppressive activity of mutant p53 in the distal gut thereby promoting
tumorigenesis. Remarkably, supplementation of gallic acid—a polyphenol metabolite
produced by Lactobacillus plantarum and Bacillus subtilis in the distal, but not the proximal
gut—was sufficient to neutralise the tumour-suppressive ability of mutant p53 and unleash
its oncogenic activity. Accordingly, gallic acid treatment led to high-grade dysplasia in
the proximal gut of CKIa∆gutp53R172H and ApcMin/+p53R172H mice and restored tumour
formation to the distal gut of antibiotic-treated CKIa∆gutp53R172H mice [255]. While key
mechanistic questions remain, these studies raise the possibility of targeting the bioactivity
and/or bioavailability of gallic acid for Wnt-driven CRCs harbouring mutant p53.
Another important advance is the development of the first microbiota-dependent
spontaneous invasive tumour model. Mice engineered to express intestinal epithelial
cell-specific ZEB2—a transcription factor that orchestrates the epithelial-mesenchymal tran-
sition (EMT)—exhibited increased barrier permeability, dysbiosis, and myeloid cell-driven
inflammation, leading to the development of invasive colonic tumours in a microbiota-
dependent manner [256]. Underscoring the importance of a dysbiotic milieu, the small-
intestinal epithelium did not show evidence of dysplasia, and antibiotic-mediated depletion
of the microbiota or germ-free rederivation abrogated tumour formation in this model [256].
Although the authors stopped short of characterizing the dysbiotic species underlying
tumour development in this model, the identification of the driver species and/or their
key oncometabolites will provide valuable mechanistic insights into dysbiosis-driven CRC.
To conclude, diverse and regionalised microbiota, their secreted metabolites, and
their virulence factors and effector proteins converge with host-derived immune cells,
ingested nutrients, cytokines, and growth factors to influence niche-signalling and ISC func-
tion in homeostasis, post-injury regeneration, and CRC. Altogether, the abovementioned
compelling findings reinforce the notion that gut microbiota can profoundly influence
tumorigenesis and are an integral part of the niche/tumour microenvironment (TME),
influencing the growth of emergent tumours in concert with the genetic make-up of the
tumour cells. They also open up the realm of manipulating the microbial and metabolite
milieu for therapeutic gain, albeit with the humbling realisation that we still have much
to learn about harnessing the crosstalk between the microbial ecosystem and the wider
niche/TME.
12. ISC Dynamics in the Niche: “Winner Takes All”
Mouse ISCs divide symmetrically generating equipotent progeny that stochastically
compete for limited niche space via “neutral-drift” kinetics, whereby each descendant has
an equal probability of achieving clonal dominance over its neighbours [257,258]. Intravital
imaging, however, elegantly showed that so-called “central ISCs” are three times more
likely to colonize a crypt than “border ISCs”, suggesting that close proximity to the niche
at the crypt base is pivotal to the ability of an ISC to colonize an entire crypt (fixation) [259].
Border ISCs are more easily displaced from the niche and are, hence, lost from the ISC pool
as they commit to differentiation, with the corollary that if differentiated cells descend back
into the niche, they can regain stemness. Interestingly, Paneth cell-secreted WNT3 does
not diffuse freely within the niche; instead, FZD-bound WNT3 levels are progressively
diluted through receptor-mediated endocytosis and Lgr5+ ISC division [260]. Thus, the
availability of WNT3 becomes limiting further from the crypt base, dictating the size of
the niche and differentially imparting distinct stemness capabilities to centre and border
ISCs [259]. Consequently, only 5–7 [261,262] of the 14–16 Lgr5+ cells per crypt [258] manifest
long-term self-renewal potential, consistent with the reported heterogeneity within the
Lgr5+ population [30,43,44].
In the mouse SI, time-to-monoclonality (the emergence of monoclonal crypts de-
scended from a single ISC) is 1–6 months [257,258]. While human colonic crypts contain
5–7 functional ISCs—similarly to mouse small-intestinal counterparts—the average time-
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to-monoclonality is in the order of six years [263,264]. In human colonic crypts, the predom-
inant mode of ISC division is asymmetric, accounting for the sluggish rate of fixation [265].
In addition, human ISCs may also proliferate at an intrinsically slower rate, as observed in
xenografted organoids [266], and are likely to be exposed to different environmental cues
and dietary nutrients compared with mouse counterparts [177,267]. Nevertheless, while
the number of functional ISCs per crypt is comparable between mice and humans, the
rate of stochastic replacement of ISCs by their neighbours is significantly lower in human
colonic crypts, rendering fixation inefficient over the longer term [264,265].
These population dynamics ensure that expansion of a particular ISC-derived clone is
balanced by the extinction of its neighbours, thus maintaining the size of the homeostatic
ISC pool constant over time. Mutant cells may be stochastically extinguished from the ISC
pool before they can accumulate additional hits, limiting aberrant expansion of mutant
lineages [262]. Indeed, caloric restriction—a dietary intervention touted for its anti-cancer
benefits and known to reduce intestinal polyp formation in APCMin/+ mice [268]—increases
the number of wild-type ISCs competing for niche occupancy, thereby decreasing the
likelihood that mutant ISCs will be aberrantly retained in the stem cell pool [269].
During colorectal adenoma-carcinoma progression, however, crypt dynamics are
subverted towards a “biased-drift” pattern. Mutations in Apc or Kras, and/or limited
availability of WNT ligands in the niche, confer a competitive advantage on mutant Lgr5+
ISCs, thereby increasing their likelihood of displacing wild-type counterparts to achieve
clonal dominance and fixation [63,262,270,271]. Interestingly, Kras-mutant crypts exhibit
an increased tendency to undergo fission, whereby the crypt epithelium bifurcates and
redistributes the Paneth cells/niche into the two daughter crypts, ensuring the expansion
of the Kras-mutant epithelium beyond the confines of a single crypt [270]. Increased crypt
fission also underlies “field cancerization” (the emergence, in the non-dysplastic mucosa,
of patches of crypts harbouring pro-oncogenic mutations) as well as the eventual formation
of adenomas initiated from mouse APC-deficient Lgr5+ ISCs [272]. Indeed, such events
are commonly observed in familial adenomatous polyposis [273]. Moreover, although p53
mutations bear no impact on crypt dynamics during homeostasis, they selectively confer a
survival advantage over non-mutant ISCs in the hypoxic inflamed colitis mucosa, which
also predisposes to tumorigenesis [262]. These findings demonstrate how pro-oncogenic
mutations and changes in the niche/microenvironment cooperate to alter crypt dynamics,
accelerate clonal fixation, and increase the frequency of crypt-fission events, promoting
adenoma progression.
13. Cells-of-Origin
Well- and moderately differentiated colorectal tumours retain some aspects of the
glandular architecture and cellular hierarchy of the normal intestinal mucosa [274]. Indeed,
analogous to normal crypts, current dogma posits that only a subset of intestinal tumour
cells—termed cancer stem cells (CSCs)—are endowed with tumour-initiating potential,
i.e., the capacity to self-renew and generate the differentiated non-CSCs that constitute the
tumour bulk. CSCs are also thought to underpin metastatic competence, drug resistance,
disease recurrence and, ultimately, poor therapeutic outcome. Multiple cell-surface proteins,
e.g., CD133 (also known as PROM1), CD166, or CD44, have been proposed to identify
distinct subsets of human colorectal CSCs, likely linking the TME with intracellular cancer-
driver pathways. However, these are beyond the scope of this article and the reader is
referred to recent excellent reviews [275–280]. Notwithstanding the CSC hypothesis, and
in line with the pervasive plasticity of the intestinal epithelium, accumulating evidence
supports both “bottom-up” [273] and “top-down” [281] histogenesis of colorectal tumours
whereby the cells-of-origin comprise either ISCs at the crypt base or differentiated cells at
the crypt apex, respectively (Figure 2c).
Lgr5+ ISCs have been amply demonstrated to serve as tumour-initiating cells [59,282].
Indeed, targeted deletion of Apc in Lgr5+ ISCs drives aberrant Wnt signalling and hyperpro-
liferation, leading to rapid adenoma formation in mice [59]. Moreover, overexpression of
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Rspo3 in Lgr5+ cells drives hyperplastic bottom-up lesions, containing mislocalized Paneth
cells and expanded Lgr5+ and Lgr4+ populations, in keeping with the fact that RSPO3
is a secreted protein that nurtures both Lgr5+ ISCs and their supportive epithelial niche.
Besides Lgr5+ cells, however, lineage tracing implicates Lgr5− populations as putative cells-
of-origin of the resulting hyperplastic adenomas and adenocarcinomas in this model [282].
Similarly, constitutive activation of Wnt signalling in cells expressing Bmi1 [12], Prom1 [283],
or Lrig1 [15,284] drives bottom-up intestinal neoplasia in mice. Collectively, these findings
suggest the existence of multiple possible cells-of-origin within the crypt.
Other crypt cell types can also assume the mantle of tumour-initiating cell, contribut-
ing to bottom-up tumorigenesis. Hence, loss of Apc in Krt15+ cells—a heterogeneous
population, encompassing Lgr5+ and Lgr5− cells, spanning the crypt base as well as the
TA zone—leads to adenomas that occasionally progress to invasive adenocarcinomas [44].
Such lesions are not typically observed upon sole deletion of Apc in other putative tumour-
initiating cell populations, including Lgr5+ ISCs [15,18,59,284]. It remains to be determined
whether the coexistence of adenomas and adenocarcinomas—frequently a feature of hu-
man polyposis syndromes—reflects tumour initiation from distinct differentially localized
subsets of Krt15+ cells [44]. Remarkably, while the majority of Lgr5+ subsets are exquisitely
sensitive to DNA damage, Krt15+Lgr5+ cells are radioresistant and may thus survive to
spawn tumours post injury.
Conversely, top-down lesions likely derive from cells located in the TA zone or the
villus, induced to undergo dedifferentiation. Notably, sole deletion of Apc in TA cells yields
only microscopic lesions, which rarely progress to adenoma [59]. Additional TGFβ dysfunc-
tion is not sufficient to drive dedifferentiation in this compartment or the formation of top-
down lesions [285]. However, following exposure to inflammation and/or upon accumulat-
ing cooperating mutations, differentiated villus cells can re-express Lgr5 and ISC markers,
and initiate tumours [286,287]. Thus, constitutive activation of β-catenin and NFκB sig-
nalling [286] or dual Apc/Kras mutations [287] can drive tumour formation both from crypt
ISCs and villus epithelial cells in the small intestine [286] and colon [287], respectively. Dele-
tion of Tgfbr1 further augments the dedifferentiation potential of VilCreERApcfl/flKrasG12D/+
villus epithelial cells, exacerbating top-down tumorigenesis [285]. This suggests that, dur-
ing early tumour progression, the elevated stromal-derived TGFβ levels that prevail further
up the crypt–villus axis restrain dedifferentiation, whereas cells in lower regions or the
crypt base can escape to form tumours. Consequently, mutations enabling differentiated
cells to evade TGFβ-mediated tumour suppression will extend the pool of tumour-initiating
cells. Importantly, the aggressive top-down tumours that emerge, following Tgfbr1 deletion,
exhibit deregulated MAPK signalling and are therefore sensitive to MEK1/2 inhibition,
providing an opportunity for early therapeutic intervention [285].
Interestingly, concurrent activation of Wnt signalling and loss of Smad4 is sufficient
to drive dedifferentiation and adenoma formation from enterocytes [288], in contrast to
the combined deletion of Apc/Tgfbr1 [285], discussed above. This suggests that SMAD4
may function downstream of BMPs, rather than TGFβ, in restraining epithelial dediffer-
entiation [288]. Notably, deletion of Smad4 in the untransformed intestinal epithelium
elicits a pronounced TNF-mediated inflammatory response that is sufficient to drive colitis-
associated carcinomas. These tumours strongly resemble human SMAD4-deficient ulcera-
tive colitis-associated CRCs, thus implicating TGFβ/BMP signalling in the suppression of
the innate immune mechanisms that become derailed in colitis [289].
Additional examples whereby dedifferentiation bestows tumorigenic potential have
been reported. Long-lived differentiated Dclk1+ tuft cells, which remain quiescent following
Apc loss, are readily transformed by inflammation, forming poorly differentiated colonic
adenocarcinomas [32]. APC truncation or post-irradiation depletion of Lgr5+ ISCs induces
radioresistant Krt19+Lgr5− upper-crypt progenitors to dedifferentiate, via an Lgr5+ state,
spawning tumours both in the small intestine and colon [18]. Bhlha15+ secretory cell
precursors are another candidate cell-of-origin located just above the ISC zone. In the
small intestine, these cells can dedifferentiate to form tumours with serrated features
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upon sustained activation of Notch signalling, combined with Apc loss. In the colon, the
counterpart Bhlha15+ cell population is mobilized upon DSS treatment via the activation
of SRC and YAP [290]. Thus, Bhlha15+ secretory cell precursors respond differently to
tumorigenic insult in distinct niches, although the clinical relevance of these findings
remains unclear [290].
As mentioned earlier, aberrant expression of the BMP inhibitor Grem1 in the intestinal
epithelium disrupts homeostatic morphogen gradients, prompting the proliferative expan-
sion of Lgr5− progenitor cells that spur the formation of ectopic crypt foci perpendicular to
the villus axis. Cells, within these structures, accumulate multiple somatic mutations, with
concomitant suppression of cytostatic and differentiation programs, eventually progressing
to polyps that recapitulate features of hereditary mixed polyposis syndrome and traditional
serrated adenomas [94]. These findings further confirm that Lgr5− cells, outwith the ISC
niche, can undergo malignant transformation.
Together, the above findings reinforce the links between deregulated niche signalling,
prolonged inflammation, and CRC risk/progression [291] (Figure 2), and reveal how field
cancerization can significantly expand the array of potential tumour-initiating cells [264].
Crucially, they underscore that the initiation of tumours from differentiated cells requires
cooperating mutations or exacerbating stimuli, such as an inflammatory drive, alongside
Wnt deregulation.
14. All Roads Lead through LGR5
Notwithstanding the existence of multiple putative cells-of-origin within the crypt
base or more differentiated luminal regions, compelling evidence supports the contention
that LGR5 marks a subset of mouse and human intestinal CSCs endowed with tumori-
genic potential and multi-lineage differentiation capacity [59,292–298]. Perhaps unsurpris-
ingly, considering the pervasive plasticity of the intestinal epithelium, ablation of Lgr5DTR
CSCs failed to achieve regression of non-metastatic ApcMin/+KrasLSL-G12D/+Vil1Crep53−/−
Lgr5DTR/eGFP subcutaneous organoid allografts. Instead, tumours remained in a state of
stasis while Lgr5− populations mobilized to sustain growth, albeit less efficiently than
Lgr5+ counterparts [297]. Notably, tumour growth resumed unabated following treatment
withdrawal, underpinned by dynamic conversion of Lgr5− non-CSCs into Lgr5+ cells.
Intriguingly, comparable growth dynamics were observed in cultured organoids, suggest-
ing that the repopulation of Lgr5+ cells may partly rely on intrinsic Lgr5− cell properties
and proceed independently of tumour-activated stroma [297]. The mechanisms whereby
non-CSCs, or distinct subsets thereof, sense the depletion of Lgr5+ CSCs within a tumour,
and the intrinsic and extrinsic cues that trigger their mobilization remain an important
avenue for investigation to better understand therapy resistance and tumour recurrence.
Similarly, xenografted patient-derived organoids contain differentiated KRT20+ cells
that can re-express LGR5 and fuel tumour regrowth [299]. In this model, short-term
ablation of LGR5+ cells, in combination with anti-EGFR therapy, elicited a more pronounced
inhibition of tumour growth than either treatment alone [299]. Consistent with this, residual
drug-resistant LGR5− cells that can reconstitute tumour growth, following LGR5+ cell
depletion, express the EGF-family member EREG [300]. Interestingly, oxaliplatin did not
synergize with anti-EGFR, owing to the failure of chemotherapy to induce LGR5 expression
in LGR5− cells [299]. Since LGR5+ and KRT20+ cells appear to reside within distinct tumour
niches [298], it is plausible that depletion of the LGR5+ population exposes differentiated
KRT20+ cells to aberrant instructive signals that incite their dedifferentiation and acquisition
of CSC traits, analogous to the reversion of multiple intestinal cell types to an Lgr5+ state
during injury-induced regeneration [9,20,26].
Until recently, little was known about the identity of metastasis-initiating cells in CRC
and their relationship to primary tumour CSCs. Selective ablation of Lgr5DTR CSCs in ortho-
topically implanted ApcMin/+KrasLSL-G12D/+Vil1Crep53−/−Smad4−/−Lgr5DTR/eGFP organoids
demonstrated an indispensable role for Lgr5+ CSCs in the formation and maintenance
of metastatic outgrowths, even though their ablation proved inefficacious in the primary
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tumour setting [297]. Most notably, treatment cessation was not accompanied by regrowth
of liver metastases, highlighting the potential therapeutic benefits of targeting Lgr5+ CSCs
in the metastatic setting [297]—the ultimate cause of patient demise. In addition, these
findings suggest that distinct tumour cell subsets may harbour differential abilities to
drive primary tumour growth and initiate metastases, and underscore the importance of a
permissive microenvironment as a prelude for colonization at the distant site [297].
Unexpectedly, ablation of Lgr5DTR CSCs did not impair primary tumour invasiveness
per se, yet still reduced liver metastatic burden, raising the possibility of LGR5-independent
mechanisms of productive invasion [297]. Indeed, using intravital multiphoton microscopy
to observe spontaneous metastatic progression from orthotopically implanted, genome-
edited CRC organoids [301], van Rheenen and colleagues made the striking observation that
the majority of circulating tumour cells lacks Lgr5. In vitro, Lgr5− cells were intrinsically
competent to form organoids and spawn functional Lgr5+ progeny, independently of niche
signals, although the emergence of Lgr5+ cells was increased in the presence of HGF and
FGF [302]. Importantly, targeted ablation of Lgr5DTR/eGFP cells prevented the progression of
micrometastases, similar to the findings of de Sousa e Melo et al. [297], with colonization
and outgrowth of seeded Lgr5− cells dependent on the de novo expression of Lgr5 [302].
While Lgr5+ CSCs were detected in the migratory population, they were not typically
recovered from the circulation, raising the intriguing possibility that, upon escaping the
confines of the primary tumour niche, Lgr5+ cells enter an Lgr5− non-CSC state that likely
confers the ability to navigate and survive the perils of the metastatic cascade. Following
seeding of Lgr5− cells at the distant site, their reversion to an Lgr5+ state allows the
outgrowth and progression of micrometastases. Although organoid cultures suggest that
Lgr5− non-CSCs can spontaneously revert to an Lgr5+ state in a niche-independent manner,
TME signals can nevertheless influence this transition in vivo. Deciphering the TME signals
that instruct the plasticity transitions between Lgr5+ and Lgr5− states, and the underlying
molecular mechanisms, may yield important insights into critical determinants of disease
progression and therapy resistance, and inform new strategies to target metastatic plasticity.
A further important advance is the identification of the cell-adhesion molecule L1CAM
as a cell-surface marker of metastasis-initiating CRC cells [166]. As such, L1CAM is en-
riched in the invasive front of primary tumours, matched metastases, small cell-clusters
invading lymphovascular vessels, and post-therapy surgical resection samples, implicating
L1CAM in both metastasis and chemoresistance [166]. Although L1CAMhi cells partially
overlap with LGR5+ CSCs in human CRC organoids, the significance of the various sub-
populations, expressing one or both markers, remains unclear.
While L1CAM knockdown does not impact adenoma initiation per se, it significantly
inhibits the growth, chemoresistance, and metastatic ability of orthotopically implanted
organoids derived from either left-sided APC-mutant or right-sided BRAF-mutant tumours,
underscoring that distinct primary tumour types may nevertheless deploy similar tactics
to navigate the metastatic cascade. At the distant site, L1CAM is thought to mediate the
heterophilic adhesion of metastasis-initiating cells to the laminin-rich ECM, facilitating
colonization and metastatic outgrowth [166].
Interestingly, L1CAMhi metastasis-initiating CRC cells express a gene signature associ-
ated with revival stem cells [156] as well as EMT, prompting the authors to draw parallels
between the plasticity programs underpinning the regenerative wound-healing response
and the disruption of epithelial cell-cell contacts, leading to cell detachment from the
primary tumour [166]. Of note, L1CAM has been shown to mediate pericyte-like spreading
of disseminated tumour cells on host tissue capillaries by activating YAP [303], a key
common denominator of the revival stem cell signature [156] and the regenerative response
to injury [149]. Accordingly, while L1CAM is not detected in the homeostatic intestinal
epithelium, its expression is markedly induced during processes that disrupt epithelial
intercellular contacts, including colitis-associated regeneration and organoid growth [166].
Mechanistically, the disruption of epithelial cell-cell contacts results in the displacement of
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E-cadherin from the cell membrane, which in turn alleviates REST-mediated repression of
the L1CAM promoter [166].
Akin to the plasticity of Lgr5− disseminated cancer cells that can replenish the dam-
aged Lgr5+ CSC pool [9,286,297,299] and seed Lgr5+ liver metastases [302], a subset of
L1CAMlo cells can re-express L1CAM and engage the regenerative gene expression pro-
gram during chemotherapy, organoid formation, and DSS-induced regeneration [166].
Organoids and tumours, surviving post chemotherapy, are highly enriched for L1CAM
expression, and the combination of irinotecan and L1CAM knockdown is more potently
cytotoxic than either treatment alone [166].
While the identification of L1CAM as a metastasis-initiating cell marker in CRC repre-
sents an exciting advance, this work raises further questions: Which L1CAMlo cell subsets
are poised to switch on L1CAM expression? Which TME cues prompt the conversion
of the L1CAMlo subsets to L1CAMhi cells, and how can they be targeted to deplete the
L1CAMhi cell pool? Is YAP involved in mediating this transition? Does REST de-repression
affect entire modules of genes that underpin metastatic competence? Which of the many
potential L1CAM binding partners contribute to metastatic competence? Can L1CAM be
used prospectively to predict treatment response and metastatic propensity, and to delin-
eate disease progression in the clinic? Finally, as L1CAM is not expressed in the normal
colonic epithelium [166], can it provide a therapeutic handle for incurable metastatic and
treatment-refractory disease?
Overall, the above findings attest to the plasticity of Lgr5− tumour-bulk cells, sug-
gesting it may underpin failed treatment outcomes and metastatic competence. Which
differentiated/non-CSC Lgr5− subsets are mobilized to replenish primary tumour growth,
when the Lgr5+ CSC pool is compromised, and whether these are the same cell subsets that
exhibit metastatic competence remains to be seen. The ability of differentiated/non-CSC
Lgr5− cells to activate a dormant plasticity program at the distant site, seed metastases, and
re-establish a cellular hierarchy de novo highlights the need to target intrinsic plasticity
mechanisms as well as extrinsic niche pathways in order to ablate metastatic potential.
15. Microenvironmental Influences on Tumour Cell Plasticity
In mouse [304] as well as human tumours [274], CSC populations are located at the
base of crypt-like structures [304], near the tumour-stroma interface, suggesting that signals
emanating from the stroma can impose stemness and/or induce
dedifferentiation [259,261,305–307]. Accordingly, accumulation of nuclear β-catenin is
most pronounced in tumour cells located near stromal myofibroblasts at the leading edge,
correlating with CSC clonogenic potential [305] and metastatic propensity [308]. Inter-
estingly, the membranes of cells staining positive for nuclear β-catenin, at the invasive
edge, are decorated with the metastasis-initiating cell-marker L1CAM, which is also a
Wnt/β-catenin target [166,309]. Furthermore, converging evidence suggests that activated
CAFs elaborate a cocktail of cytokines, including HGF, OPN, SDF1, and IL17A, which
stimulates Wnt/β-catenin signalling and confers enhanced clonogenic potential, therapy
resistance, and metastatic competence upon nearby CSCs as well as bestowing CSC traits
upon differentiated tumour cells [305,307,310,311]. Conversely, KRT20 is expressed in dif-
ferentiated cells of the tumour core [274]. These findings underscore the defining influence
of stromal signals in the development of aggressive CSC traits and bring forth the concept
of the “migrating cancer stem cell” as a key player in metastatic competence [308].
LGR5-expression patterns differ between human non-serrated conventional adenomas
and serrated lesions (sessile serrated adenomas/polyps and traditional serrated adenomas),
likely reflecting differences in their histogenesis and their niche/TME. In conventional
adenomas, expression of LGR5 is spread throughout the gland, suggesting an expanded
niche and the lack of a cellular hierarchy [312]. In contrast, serrated lesions retain basal
localization of LGR5 and display a presumptive cellular hierarchy [312]. In particular,
the ectopic crypts of traditional serrated adenomas harbour basal LGR5+ cells, potentially
linking the disruption of BMP gradients to the de novo generation of an ectopic niche
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and/or the migration of LGR5+ cells to a permissive site in response to chemotactic TME
signals [87,312]. In addition, consistent with a role for LGR5 in invasion, LGR5 expression
is enriched in CD44hiKRT20lo cells at the invasive edge of adenocarcinomas, irrespective of
stage [312].
Since inflammation is a key determinant of a pro-tumorigenic environment, it is per-
haps unsurprising that the inflammatory mediator PGE2 drives expansion of multiple CSC
populations (expressing LGR5, CD133, CD44, and SOX2) and promotes liver metastasis in
orthotopic tumour models [313]. Interestingly, celecoxib—a nonsteroidal anti-inflammatory
drug known to inhibit prostaglandin synthesis—attenuated these effects [313], illuminat-
ing the mechanisms whereby such drugs reduce the risk of CRC. As already discussed,
PGE2 also drives tumour initiation from foetal-like, regenerative Sca1+ reserve-like stem
cells by stimulating the druggable PTGER4–YAP signalling axis [159]. Taken together, the
abovementioned studies contend that cancer stemness is a dynamic cellular state, defined
by the microenvironment rather than a particular CSC-marker phenotype or cell-of-origin.
16. CRC Subtypes and Niche-Signalling Pathways
Recent large-scale molecular profiling endeavours have classified CRCs into distinct
subtypes with a view to relating molecular traits to clinical behaviour and therapy re-
sponses [237,314,315]. Hence, four so-called consensus molecular subtypes (CMS) have
emerged from a comprehensive multipronged analysis of tumour molecular and pheno-
typic features (including gene expression, mutations, copy number, methylation, microR-
NAs, proteomics) [237]. Moreover, five CRC intrinsic subtypes (CRIS) have been proposed
based on tumour cell-intrinsic transcriptional signatures, independently of any stromal
contribution [315].
Hypermutated CMS1 tumours exhibit a serrated morphology and, typically, har-
bour BRAFV600E mutations, mismatch-repair deficiency, and CpG-island hypermethylation,
leading to loss of tumour-suppressor gene function. The CMS1 TME is enriched for infil-
trating immune cells (mainly TH1 and cytotoxic T cells), while also exhibiting pronounced
activation of immune-evasion pathways, suggesting CMS1 tumours may be amenable
to immune-checkpoint inhibitors, which restore T cell-mediated antitumor immune re-
sponses [237]. By contrast, the microenvironment of mesenchymal CMS4 tumours is
proinflammatory with prominent activation of complement pathways, immune and stro-
mal infiltration, and increased ECM deposition. In addition, CMS4 tumours are enriched
for signatures associated with EMT, TGFβ signalling, angiogenesis [237], and YAP/TAZ ac-
tivity [316]. Hence, CMS4 tumours carry the worst prognosis due to a heightened metastatic
propensity and an inherent resistance to chemotherapy and EGFR-blockers [237,314,317].
While CMS4 tumours phenotypically and behaviourally resemble the intrinsic CRIS-
B subtype, it is important to note that their elevated TGFβ levels emanate from the
stroma [315,318–320]. In contrast, CRIS-B tumours harbour tumour cell-intrinsic deregu-
lation of the TGFβ pathway [315]. Thus, the CRIS-B signature confers a poor prognosis
in tumours with a low CAF-content and, conversely, high CAF infiltration predicts worse
outcome only in non-CRIS-B tumours [315]. Nevertheless, recent works have validated the
CMS-classifiers, successfully assigning multiple cell lines, primary cultures, and patient-
derived xenografts to the corresponding CMS, based on their gene-expression signatures
independently of stromal contribution [321].
CMS2 tumours are believed to arise via the conventional adenoma-carcinoma se-
quence, typically entailing aberrant activation of Wnt signalling [237]. Indeed, these
tumours most resemble the CRIS-C, CRIS-D, and CRIS-E subtypes, since they are all under-
pinned by activated Wnt/β-catenin signalling [237,315,322]. In addition to Wnt activation,
CRIS-C tumours exhibit elevated EGFR/ERBB signalling and MYC copy number gains, but
typically retain wild-type KRAS, which predicts a good response to EGFR-targeted thera-
pies [315,322]. CRIS-D tumours are enriched for amplification of Chr11p15.5, encompassing
the IGF2 locus, and exhibit activated IGF2 as well as FGFR signalling [315]. Importantly,
CRIS-D tumours also express an ISC-associated gene signature, which correlates with
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disease recurrence [304,315]. Of note, IGF2 and ASCL2 are co-expressed in a subset of
aggressive CRC liver metastases with Chr11p15.5 gain [323]. Consequently, therapies tar-
geting the IGF2-receptor, IGF1R, and FGFR may be combined with LGR5-targeted regimens
for CRIS-D patients. Lastly, CRIS-E tumours frequently harbour KRAS and p53 mutations,
rendering them refractory to anti-EGFR therapies. Interestingly, they also exhibit a Paneth
cell-like gene expression profile [315,322], suggesting they may develop from metaplastic
Paneth cells, well-documented in CRC histopathology [65,324]. Overall, these Wnt-driven
subtypes could benefit from combinatorial strategies to perturb downstream effectors of
the Wnt/β-catenin program as well as autocrine-signalling pathways, enriched in specific
CRIS subgroups [63,237,315,322].
Finally, CMS3 tumours most resemble the CRIS-A subtype [315], lacking immune and
inflammatory signatures and often harbouring KRAS-activating mutations, which confer
resistance to anti-EGFR therapies [237]. Nevertheless, the so-called metabolic subtype is
enriched for several metabolic pathways, including glutamine, fatty acid, and lysophos-
pholipid metabolism, which opens up the realm of metabolic-targeted therapies [237,314].
17. Niche-Emancipating Mutations, Tumour Progression, and
Therapeutic Implications
As discussed above, the CSC niche is pivotal in driving intra-tumoral heterogeneity
within genetically homogeneous colorectal tumours. Several studies support the notion
that colorectal tumours contain multiple coexisting genomic subclones, likely arising from
functionally distinct CSC populations that differ in their self-renewal capacity, metastatic
potential, and intrinsic chemoresistance [325–329]. Indeed, chemotherapy promotes clonal
dominance of minor intrinsically resistant or dormant subclones [326]. Moreover, one study
reported that 65% of distant and lymphatic metastases originate from independent sub-
clones within the primary tumour, whereas only 35% derive from the same subclone [330].
Overall, clonal evolution and heterogeneity of colorectal tumours are thought to adhere
to the “Big Bang” model, whereby the majority of pervasive mutations arise early during
tumour development, with aggressive subclones emerging primarily when a new selective
pressure—e.g., chemotherapy—is applied [331].
Engineered organoids, harbouring cooperating driver-mutations in key CRC pathways
(Wnt, EGFR, p53, TGFβ, and/or PI3K), recapitulate the adenoma-carcinoma transition
and exhibit a progressive loss of niche dependence, which confers a growth advantage in
a hostile milieu [332–335]. While such engrafted organoids exhibit invasive features and
can form micrometastases [332–335], additional molecular lesions and TME changes are
required to drive colonization and metastatic outgrowth [296,336–338]. For example, p53
loss allows continued proliferation and survival under stress as well as the accumulation
of additional emancipating mutations that confer a competitive clonal advantage, in keep-
ing with the Big Bang model [331,339]. The fact that overexpression of the BMP/TGFβ
inhibitor NOG enables liver colonization of SMAD4-proficient APC−/−KRASG12D/+p53−/−
organoids, similarly to APC−/−KRASG12D/+p53−/−SMAD4−/− counterparts, identifies the
acquisition of niche independence as a key determinant of metastatic competence [339].
Understanding how CSCs circumvent niche dependence (Figure 4) will likely in-
form the development of novel targeted therapies. Mutations in APC or CTNNB1 lead
to cell-autonomous constitutive activation of pro-proliferative Wnt signalling, setting
cells along the path to niche independence. Yet, remarkably, restoring APC function to
shApcKrasG12Dp53R172H/− invasive carcinoma models suffices to induce cell differentiation,
restore niche homeostasis, and elicit tumour regression, attesting to the therapeutic poten-
tial of targeting the Wnt pathway in CRC [336,340]. In the case of metastases, however,
this differentiation therapy approach generated ectopic, functional colonic epithelium at
the distant site, raising a cautionary note about possible collateral damage to the host
tissue [336]. Furthermore, the development of therapies for ligand-independent CRCs
that harbour constitutive Wnt-pathway activation has been fraught with the challenges
of targeting complex intracellular signalling hubs as well as the toxicity associated with
inhibiting the “ubiquitous” Wnt pathway [322].
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Notably, APC and CTNNB1 mutations are mutually exclusive with perturbations of
the extrace lular arm of the Wnt pathway [341]. Indeed, chromosomal translocations th
increase RSPO expression, or mutations that block ZNRF3/RNF43-mediated ubiquitina-
tion and degradation of FZDs, augment Wnt signalling in APC-proficient tumours that
therefore, crucially, retain ligand-dependence [282,342–347]. Unveiling new therapeutic
vulnerabilities, these findings prompted the development of RSPO-targeted therapies
for the 10% of APC-proficient colon tumours harbouring RSPO2 and RSPO3 gene fu-
sions [343]. Encouragingly, antibody-mediated blockade of RSPO3 inhibited the growth of
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PTPRK-RSPO3-fusion-positive human tumour xenografts, compromising the expression
of stemness genes (e.g., LGR5, ASCL2, LRIG1, TERT) and promoting differentiation [348].
Moreover, PORCN inhibitors [342,349] and anti-LRP5/6 antibodies [350] have shown
promising efficacy in preclinical models of Wnt-addicted tumours. Collectively, these
emergent therapies act to exhaust CSCs, downregulate CSC-associated genes, induce
differentiation, and restore crypt homeostasis, thus holding promise as candidate differen-
tiation therapeutics.
Kleeman et al. reasoned that translating these discoveries to the clinic will require a
“mutation-agnostic biomarker” to stratify patients with ligand-dependent tumours [341].
Towards this aim, they profiled the differential expression of Wnt-target genes between
ligand-independent and -dependent tumours. Strikingly, they found that ligand-dependent
tumours tend to silence genes encoding Wnt antagonists, such as AXIN2, NKD1, APCDD1,
NOTUM, and DKK4, whereas ligand-independent tumours effectively bypass Wnt-pathway
negative feedback loops without the need for such selective pressure. As a result of this
work, AXIN2 hypermethylation/silencing is proposed as a tractable biomarker of ligand-
dependent tumours that may help prospectively stratify patients for therapies perturbing
Wnt-pathway ligands, including PORCN inhibitors [341].
Despite their tolerability, the safety of Wnt-targeted therapies remains under scrutiny,
since on-target effects include diminished bone density and volume [351] as well as an
unknown impact on Wnt-regulated stem cell populations in bystander organs. Safety con-
cerns aside, the rationale of targeting Wnt signalling in the metastatic setting has further
been challenged. Thus, while an Lgr5+EPHB2+ ISC-associated signature correlates with
an increased risk of disease recurrence [304], a subset of poor-prognosis human metastatic
CRCs, expressing nuclear β-catenin, harbours methylation of certain Wnt-target genes,
including LGR5, ASCL2, and the negative feedback regulators AXIN2 and APCDD1 [352].
Accordingly, 5-azacytidine demethylation derepressed AXIN2 and APCDD1 and com-
promised xenograft growth [352]. Strikingly, while high expression of the majority of
Wnt/CSC-associated genes correlated with good prognosis, the CSC population of these
poor-prognosis tumours expressed an immature, embryonic stem cell-like signature, dis-
tinguished by markers of pluripotency (namely, targets of the transcriptional regulators
SOX2, OCT4, and NANOG) as well as the selective methylation of Wnt/CSC-associated
genes [352]. Thus, Lgr5+EPHB2+ ISC-associated signatures may be indicative of intestinal
tissue-specific Lgr5+ ISCs as a likely cell-of-origin, whereas the immature signatures may
suggest reactivation of dormant embryonic programs. Most importantly perhaps, these
findings point to Wnt-independent signals regulating Wnt-target genes during the transi-
tion of adenomas to poorly differentiated, aggressive tumours. Similarly, patient-derived
CD133+ CSCs harbour an embryonic stem cell-like signature, enriched for targets of SOX2,
OCT4, and NANOG [353] as well as high HH/GLI1 signalling [353]. Here, consistent
with the aforementioned findings [352], dominant-negative TCF4 enhanced metastasis
despite blocking Wnt signalling in CD133+ CSCs [353]. Together, these studies suggest that
anti-metastatic strategies should target pathways driving the immature CSC signature, e.g.,
HH/GLI1 signalling, rather than the Wnt/TCF axis [352,353], although Wnt agonists may
also be deployed depending on the context [322,352].
Recent studies have further shown that the attenuated expression of LGR5, observed
in advanced CRCs, often correlates with markers of TGFβ activation [354]. Indeed, LGR5
knockdown compromised TGFβ signalling and, similarly to the abovementioned studies,
increased metastasis in an orthotopically implanted cell line model [354]. Here, in addition
to its roles in potentiating Wnt signalling, RSPO1 was found to stimulate the formation
of complexes between LGR5 and the TGFβ type II receptor, augmenting the cytostatic
and cytotoxic effects of TGFβ while effectively providing a selective pressure for silencing
LGR5 during CRC progression [354]. At first, the emergent conclusion that LGR5 and/or
RSPO1/LGR5 complexes function effectively as metastasis suppressors [352–354] may
seem at odds with the finding that targeting LGR5 leads to regression of established liver
metastases [297]. However, the former studies blocked LGR5-associated downstream
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pathways in human CSCs [352–354], whereas the latter study ablated entire Lgr5+ CSC
subsets within engineered mouse organoid allografts [297]. Of note, it is also likely that
LGR5 expression levels, isoform ratios, and functions are differentially and dynamically
regulated in different CRC subtypes, disease stages, CSC subpopulations, stages of the
cell cycle, and, even, distant sites [355]. Nevertheless, collectively, these studies identify
repression of Wnt signalling in advanced and metastatic CRCs, contrary to the just-right
levels driving adenoma formation, with the corollary that the same Wnt antagonists that
retard primary tumour/adenoma growth may exacerbate metastasis [352,353,356]. Taken
together with the just-right paradigm, which suggests that too much Wnt signalling can
counter polyp formation [61], it has been provocatively proposed that Wnt agonists be
evaluated in the metastatic setting, in combination with chemoradiotherapy and surgical
resection of the primary tumour [322].
Strategies that target Wnt signalling also alter competition between ISCs with pro-
found therapeutic implications. In mouse models, inhibition of WNT-ligand secretion (us-
ing PORCN inhibitors) [63] or RSPO-binding (using soluble RSPO-receptor
ectodomains) [66] reduces the number of functional ISCs per crypt. Specifically, whereas
proliferation of centre ISCs is maintained, border ISCs differentiate due to limited avail-
ability of WNT ligand/signal further from the crypt base [63]. Counter to therapeutic
intent, reduction of WNT-ligand secretion allows rapid fixation of APC-deficient Lgr5+
ISCs, owing presumably to decreased competition in the ISC pool, thereby accelerating
polyp formation [63]. Nevertheless, Wnt inhibition does reduce the incidence of crypt
fission associated with aberrant MAPK signalling [63]. As in the metastatic setting, these
data argue against employing Wnt inhibitors for APC-deficient tumours, but advocate their
use for BRAF/KRAS-mutated serrated tumours that lack APC mutation (encompassing
subsets of CMS1, CMS3, and CMS4 tumours) [63].
Although activating Notch mutations are rare, elevated levels of Notch-pathway
components (JAG1/2, NOTCH1, HES1) are detected in human colon adenomas and ade-
nocarcinomas [357,358]. Inactivation of FBXW7, which mediates the ubiquitination and
proteasomal degradation of NICD, may conceivably underlie aberrant Notch activation in
human CRCs [359]. Interestingly, active Notch signalling is associated with CRC chemore-
sistance [360] and metastasis [361], suggesting that its inhibition may confer therapeutic
benefit in advanced, treatment-refractory disease. Constitutive activation of Notch sig-
nalling alone, however, is not sufficient to initiate intestinal adenomas. Nevertheless, in
concert with Apc mutation, activated Notch accelerates adenoma formation in the small
intestine and, additionally, causes dysplastic lesions in the colon not typically observed
in mouse models, but of clear relevance to human colonic tumours [357]. Conversely, a
γ-secretase inhibitor, which prevents Notch proteolytic activation, elicits differentiation of
proliferative cells into post-mitotic goblet cells, stalling adenoma progression in ApcMin/+
mice [74]. Thus, together with Wnt signalling, the Notch pathway controls the proliferation
of the undifferentiated cells that drive the growth of ApcMin/+ adenomas.
More recently, Notch signalling has been implicated in tumour cell plasticity. Indeed,
Notch1 marks a subset of CSCs in mouse models, typified by reduced Lgr5 expression
and activated TGFβ signalling [362]. Whether these CSCs represent the same metastasis-
prone “Lgr5−TGFβ+” population that was discussed above [352,354] awaits further studies.
Additionally, in human CRCs, Notch activity is associated with intra-tumoral heterogeneity
and CSC plasticity. In xenograft models, Notch signalling promotes asymmetric division,
thus yielding both fast-cycling MYC-dependent daughters (expressing LGR5, CD133,
and CD44) and slow-cycling progeny (expressing BMI1, hTERT, and HOPX). These two
populations can readily interconvert, reminiscent of the homeostatic and +4/reserve ISCs
in the normal intestine [363]. Interestingly, Notch inhibition skews the balance in favour of
LGR5+ cells, with the corollary that targeted therapies may dispel one CSC pool but enrich
for another [363]. Similar conclusions can be drawn from the intra-tumoral distribution of
Notch activity within human xenografts: high Notch activity demarcates centrally located
epithelial tumour cells [364], whereas high Wnt/MAPK signalling is restricted to cells
Cancers 2021, 13, 1000 35 of 55
undergoing EMT at the tumour edge, consistent with aforementioned studies [305,308,364].
Here, inhibition of MAPK signalling had little-to-no effect on tumour growth and, instead,
led to a marked increase in cells with high Notch activity. Conversely, Notch inhibition
led to an enrichment of tumour cells with high MAPK activity, implicating tumour cell
plasticity in therapy resistance. Nevertheless, combined inhibition of Notch and MAPK
signalling compromised tumour growth more than either treatment alone, underscoring
the promise of combination therapies targeting plasticity [364].
In mice, APC-deficient intestinal adenomas harbour widespread overexpression of
the Notch ligand Jag1, consistent with expansion of the Paneth cell niche and activation of
Notch signalling in Lgr5+ cells. Interestingly, deletion of Jag1—but not the canonical Notch
effector Rbpj—in APC-deficient Lgr5+ cells disrupted the Paneth-cell tumour niche and
compromised adenoma growth, suggesting non-canonical Notch signalling as a prospective
therapeutic target [365]. Another study modelled the impact of targeting the Notch pathway
in distinct CSC subpopulations. Whereas Hes1 deletion in normal Lgr5+ or Bmi1+ ISCs
compromised self-renewal without impacting homeostasis, deletion of Hes1 in the Lgr5+
or Dclk1+ CSCs of ApcMin/+ adenomas elicited apoptosis, alleviating tumour burden [366].
Therefore, relatively well-tolerated γ-secretase inhibitors of Notch signalling may serve as
differentiation- and apoptosis-inducing therapies for Wnt-activated CMS2 tumours.
Notwithstanding the above, Vil1CreNotch1fl/fl mice spontaneously develop serrated
lesions and secretory cell hyperplasia, which progress to colorectal mucinous adenocar-
cinomas, characterized by marked expression of proliferative (Cdc2, Myc, Ccnb1, Ccne),
angiogenic (Ang4), proinflammatory (Cox2, Hif1α), and pro-invasive (Areg, Ereg, Wnt5a,
Mmp10) genes [367]. Accordingly, NOTCH1 mRNA expression is reduced in human col-
orectal mucinous adenocarcinomas, compared with non-mucinous tumours, suggesting a
tumour suppressor role for Notch in these human CRC subsets [367]. Collectively, these
findings reveal the context-dependent roles of Notch signalling in CRC progression and
underscore the importance of stratifying tumours according to Notch-pathway activity.
Key BMP-pathway components are commonly mutated in hereditary [96,368–371]
and sporadic intestinal cancers [372–374], where inactivation of BMP signalling correlates
with adenoma-carcinoma progression. Nonsense mutations of SMAD4 or BMPR1A are
prevalent in familial juvenile polyposis [96,369], whereas polymorphisms or duplications
upstream of the GREM1 promoter are associated with aberrant Wnt-driven GREM1 expres-
sion in hereditary mixed polyposis [375,376]. Both syndromes predispose to a plethora of
colonic tumours. GREM1 overexpression is also observed in the epithelium of traditional
serrated adenomas, which are hence regarded as the sporadic counterparts of hereditary
mixed polyposis polyps [94]. Alternatively, BMP2 may be silenced by methylation [377].
Accordingly, reversal of BMP2 methylation [377] or addition of recombinant BMP4 [378] in-
duced differentiation and apoptosis, sensitizing xenograft tumours to chemotherapy [377].
Reactivation of BMP signalling may, therefore, serve as a differentiation therapy for BMP-
deficient CRCs.
BMP activity is nevertheless highly context-dependent, and its interplay with the
Wnt/β-catenin pathway impacts different stages of CRC progression. Early in tumour
development, in a wild-type SMAD4 context, BMP signalling functions as a tumour
suppressor, inhibiting Wnt activity [379] but also suppressing stemness genes indepen-
dently of Wnt/β-catenin [95]. However, loss of Smad4 converts BMP signalling from a
tumour suppressor to a metastasis promoter. As such, SMAD4-independent BMP sig-
nalling augmented Wnt/β-catenin signalling at the invasive front [379,380] and activated
Rho/ROCK/LIMK kinases, ultimately promoting cytoskeletal remodelling, EMT, invasion,
and metastasis [381]. Accordingly, the selective ROCK inhibitor Y-27632 suppressed liver
metastasis in an orthotopic mouse model of SMAD4-deficient CRC [381]. Such approaches
may thus be effective against SMAD4-deficient tumours harbouring elevated BMPR levels
that presently confer a worse prognosis, compared with counterparts exhibiting low BMPR
expression [381].
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The effects of TGFβ signalling in CRC are similarly context-dependent, with both
tumour-suppressing and -promoting roles ascribed. Whereas many CRCs harbour inacti-
vating mutations in TGFβ-pathway components, advanced tumours often display elevated
stromal TGFβ-levels. In CRC xenografts, stromal TGFβ orchestrated a pro-metastatic
program: it stimulated CAFs to secrete IL11, enhancing the STAT3-dependent survival of
recipient tumour cells during metastasis initiation and colonization at both liver and lung
distant sites [318]. Accordingly, stromal TGFβ response signatures are predictive of disease
relapse and metastasis in CRC [318], and the presence of CAFs in the TME correlates
with an increased frequency of functional CSCs within tumours, a phenotype exacerbated
in a TGFβ-rich stroma [319]. Notably, pharmacological inhibition of stromal TGFβ can
attenuate disease progression in patient-derived tumour organoids and xenografts [319].
TGFβ is also an important instructive cue in the progression of premalignant lesions
to distinct CMS subtypes [382]. Consistent with a tumour-suppressor role in conventional
CMS2 CRCs, TGFβ induced apoptosis in tubular adenoma organoids (CMS2 precur-
sors). By contrast, higher levels of TGFβ, such as those encountered in TGFβ-activated
stroma, induced EMT—and not apoptosis—in BRAFV600E-mutant sessile serrated ade-
noma organoids, installing a mesenchymal CMS4 signature, whereas lower levels of TGFβ
promoted progression to the CMS1 subtype [382]. Indeed, a TGFβ-activated stroma is a
prominent feature of CMS4 xenografts, wherein elevated stromal TGFβ levels discourage
T-cell infiltration, enabling tumours to evade the host immune response [237]. Conse-
quently, TGFβ blockade evoked a cytotoxic T-cell response that prevented metastasis
and sensitized established liver metastases to anti-PD1/PD-L1 therapy, highlighting the
potential for combining TGFβ inhibitors with immunotherapies to curtail CMS4 progres-
sion/metastasis [337]. Similarly, while suppressed in most CRCs, BMP signalling is also en-
riched in mesenchymal CMS4 tumours, wherein the BMP and Notch pathways cooperate to
induce an EMT phenotype, crucially deploying SMAD5 in a γ-secretase-independent man-
ner, which renders these highly metastatic/aggressive subtypes refractory to γ-secretase
inhibition [383].
Constitutive activation of NOTCH1 in the intestinal epithelium of mice, harbouring
KRASG12D activation and p53 deficiency (VilCreERKrasG12D/+p53fl/flRosa26N1icd/+ ; KPN),
generated highly invasive, poorly differentiated, serrated intestinal adenocarcinomas that
readily metastasize to the liver and recapitulate the poor-prognosis CMS4 and CRIS-B
subtypes of human CRC [384]. In this first-of-its-kind autochthonous model, hyperactive
NOTCH1 remodels the TME and drives the production of neutrophil chemoattractants—
notably the CXCR2-ligand CXCL5 and TGFβ2—leading to the accumulation of immuno-
suppressive neutrophils within the pre-metastatic niche that drive immune evasion and
metastasis. Targeting Ly6G+ neutrophil populations, using a small-molecule CXCR2 in-
hibitor, an ALK5 inhibitor, a TGFβ ligand-trap, or anti-Ly6G antibodies, attracted cytotoxic
CD4+ and CD8+ T cells to the pre-metastatic niche and markedly reduced metastasis,
providing new paths to therapy, albeit without impacting primary tumour burden [384].
Lymph node metastases of the CMS4 subtype were also described in mice, harbouring
constitutive AKT1 activation and p53 deletion, following exposure to azoxymethane [385].
In line with the KPN model, emergent p53∆IECAktE17K tumours exhibited an immunosup-
pressive TME, characterized by elevated TGFβ levels and decreased T-cell infiltration,
while also showing altered recruitment of multiple immune cell types. p53∆IECAktE17K
tumours also express elevated levels of NOTCH3, which correlates with poor patient sur-
vival and the CMS4 subtype, reinforcing the involvement of deregulated Notch signalling
in this setting. Promisingly, antibody-mediated blockade of NOTCH3 markedly reduced
invasion and metastasis in this model [385]. Further preclinical insights gleaned from such
autochthonous, immunocompetent models will inform how epithelial tumour cell-intrinsic
signalling rewires the TME and identify key stromal determinants that impact immune
evasion, subtype specification, tumour progression, and therapeutic outcome while also
offering new strategies to target epithelial-stromal crosstalk.
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18. Conclusions
The pervasive plasticity of the intestinal epithelium is a double-edged sword: on
the one hand, it allows the intestine to withstand constant chemical and mechanical as-
sault and, on the other, it dooms CSC-targeted therapies to failure since depleted CSCs
can be so readily replenished. Moreover, the fact that colorectal CSCs subvert the same
niche-signalling pathways that sustain their normal counterparts poses a major thera-
peutic challenge since CSC-targeted therapies may inadvertently harm normal intestinal
homeostasis or stem cells in bystander organs. In this regard, the YAP-dependent, highly
plastic, foetal-like phenotype, implicated both in regeneration and cancer, holds promise
as an actionable target since it is both potentially druggable [159] and without apparent
detriment to homeostasis [153,386].
Developing CSC-targeted therapies that do not damage normal stem cells presents a
challenge owing to the paucity of CSC-specific markers. In this respect, the identification of
DCLK1 as a CSC-specific marker in ApcMin/+ polyps—not expressed in normal ISCs—offers
hope since ablation of Dclk1+ cells (which also express Lgr5, CD44, and CD133) caused
polyp regression, with no significant toxicity to healthy tissues [387]. Whereas this study
provides proof-of-concept for targeting Dclk1+ CSCs, the recent follow-up work identifying
IL17RB as a membrane marker of Dclk1+ CSCs offers a potential therapeutic handle for
the subset of CRCs harbouring tuft cell-like IL17RB+DCLK1+ CSCs [388]. Moreover,
the identification of L1CAM as a marker of metastasis-initiating cells, not expressed in
the normal colonic epithelium, may open new therapeutic avenues for lethal metastatic
disease [166].
In addition to fuelling primary tumour growth, CSCs are implicated in therapy
resistance, disease recurrence, and metastasis. As such, their eradication represents a “Holy
Grail” of cancer therapy. Strategies solely targeting CSCs should be wary of their inherent
plasticity, which may render such therapies futile. Instead, simultaneously targeting
multiple TME cues, underpinning plasticity or facilitating niche-independence, may be
fruitful. Indeed, preclinical evidence supports this contention, albeit currently only for
specific CRC subsets [337,342,348–350,384,385]. The mechanisms enabling colorectal CSCs
to subvert or circumvent niche-signalling dependencies will illuminate putative targets
downstream of key niche-emancipating mutations. Similarly, mechanisms empowering
disseminated CSCs to navigate the metastatic cascade and harness the microenvironment,
at the distant site, will inform therapeutic strategies for metastatic disease.
Important concerns remain as to whether, or not, to target Wnt signalling and in
which settings/subtypes this might prove beneficial or harmful. Key to solving this
conundrum will be to stratify poorly differentiated tumours, according to whether they
cluster with Lgr5+EPHB2+ ISCs [304] or display methylation of CSC-associated Wnt-target
genes [304,341], to identify patients that may benefit from Wnt antagonists or agonists,
respectively. Further studies should model the relevant CRC subtypes and delineate key
TME signals that instigate the epigenetic silencing of Wnt/CSC-associated genes during
disease progression. Downstream effectors or epigenetic modulators, discovered thereof,
may serve as prospective therapeutic targets for subtypes harbouring these immature CSC
signatures [304]. In this respect, the identification of HH/GLI1 signalling as a driver of
immature CSC signatures is promising [353]. Alternatively, as some of the methylated genes
are negative regulators of the Wnt pathway [341], their suppression may unleash gene
products that promote disease progression but offer new therapeutic targets. Epigenetic
modulation is likely key to the marked plasticity of CSC (sub)populations and may serve as
a combination therapy to channel CSCs towards a specific fate. Moreover, evaluating Wnt
agonists for the treatment of advanced intestinal tumours will require the development of
suitable subtype-specific metastatic models, which are still largely lacking.
Lgr5+ CSCs have been specifically linked to metastasis, although this does not preclude
the involvement of other CSC subsets. Nevertheless, most promising is the report that
ablation of Lgr5+ CSCs stunts liver colonization and causes regression of established metas-
tases, especially since metastasis remains the leading cause of CRC-related deaths [297].
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Moreover, the fact that Lgr5− differentiated tumour cells must re-express Lgr5 in order to
repopulate the CSC pool, following its depletion during treatment [297], or to colonize
the distant site [302] holds promise for ongoing efforts to develop LGR5 antibody-drug
conjugates [293,355,389]. However, it will be important to determine which LGR5− subsets
are able to seed metastases in distant organs, and to evaluate the long-term efficacy and
safety of targeting LGR5+ populations. Given that LGR5+ cells can be readily replenished,
it is expected that therapy will need to be sustained for the longer term [355].
In line with the plasticity of the epithelium, multiple CSC populations have been iden-
tified within intestinal tumours, although the degree to which they overlap, or interconvert,
remains unclear. It is important to note that the distribution of multiple progenitor pools
along the intestinal crypt axis implies the existence of multiple spatially distinct niches,
potentially governed by different molecular circuitries. In addition, basal proliferation rates,
crypt dynamics, stem-cell numbers, Wnt-pathway activity and niche-signalling output, cell
lineage subsets, and microbiota burden and composition vary profoundly along the length
of the intestinal tract [62,137,220,261]. In tumours, such differences are further exacerbated
by local variations in inflammation, hypoxia, altered ECM deposition, infiltrating cell types,
and activated CAFs, all of which contribute to intra-tumoral and inter-patient heterogeneity.
These considerations underscore the need to target multiple niche-signalling pathways
simultaneously to block the interconversion of distinct CSC subsets within the TME.
The capacity of CSCs to dynamically interconvert or withdraw from the cell cycle,
under the influence of niche signals and extraneous stresses such as chemotherapy, is a
critical determinant of disease progression and therapy resistance. Importantly, evidence
suggests that neoadjuvant chemotherapy enriches for a CMS4-like mesenchymal pheno-
type in residual tumour cell populations and liver metastases, irrespective of the original
CMS designation [390]. Therefore, it is possible that CMS4-targeted therapies may be
effective not only against CMS4 tumours per se, but also against the mesenchymal tumours
and metastases that persist/emerge in CRC patients of any subtype after treatment with
conventional chemotherapy [390].
The contributions of distinct CSC subsets to the emergence and clinical responses
of specific CRC subtypes, whether the various subtypes derive from particular cells-of-
origin, and whether distinct CSC populations drive primary and metastatic outgrowths are
open questions in the field. The answers will inform the development of subtype-specific
CSC-targeted therapies and enable clinicians to stratify patients most likely to benefit from
tailored therapeutics. While this review celebrates the strides of progress in the field, much
work remains to better understand the plasticity of CSCs and target their emancipation
from the niche, with a view to successfully translating findings “from crypt-to-clinic”.
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